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ABSTRACT
IMIDACLORPID, A NEONICOTINOID INSECTICIDE, IMPAIRS LIPID AND GLUCOSE
METABOLISM

September 2017
QUANCAI SUN
B.S., NORTHWEST A & F UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Yeonhwa Park
Emerging evidence suggests that environmental pollutants, including insecticides, are
linked to excessive weight gain and altered glucose homeostasis. However, there is currently
limited knowledge regarding the biochemical mechanisms by which exposure to insecticides
contribute to obesity and its associated pathologies. We first studied the influence of fipronil (a
phenylpyrazole family insecticide) on 3T3-L1 adipogenesis. Recently imidacloprid, a
neonicotinoid insecticide, was reported to potentiate adipogenesis and insulin resistance in vitro.
The current studies also determined the effects of imidacloprid exposure and its interaction with
dietary fat in the development of adiposity and insulin resistance using both male and female
C57BL/6J mice. Current results suggest that fipronil and imidacloprid alters adipogenesis and
results in increased lipid accumulation via a AMPKα-mediated pathway in cell culture models.
The current results also suggest that imidacloprid significantly promoted high fat diet-induced
body weight gain and adiposity in mice (both males and females). In addition, imidacloprid
treatment with high fat diet resulted in impaired glucose metabolism in male C57BL/6J mice.
Consistently, there were significant effects of imidacloprid on key regulators of lipid and glucose
metabolisms, including AMP-activated protein kinase-α (AMPKα) in the white adipose tissue and
the liver.
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CHAPTER 1
INTRODUCTION
The incidence of overweight and obesity has increased dramatically in recent decades and
become one of the leading health problems all over the world [1]. Lifestyle and dietary changes
alone cannot account for the dramatic rise of overweight and obesity worldwide [2]. An
increasing number of literatures have shown the relationships between exposure to environmental
pollutants, including pesticides, and obesity in humans and animals [3-7]. However, there is
currently limited knowledge regarding the biochemical mechanisms, by which exposure to
pesticides contribute to obesity and its associated pathologies. Thus, understanding these
mechanisms will be critical in providing background knowledge that may guide future
mechanistic and/or epidemiological studies, which will lead to development of effective strategies
for treating and/or preventing these diseases in the future [8].
Our previous studies reported that imidacloprid, a neonicotinoid insecticide, promotes
adipogenesis in 3T3-L1 adipocytes and induces insulin resistance in C2C12 myotubes [7, 9].
However, it is not known whether fipronil (phenylpyrazole family insecticide) could also
promotes adipogenesis and if imidacloprid exposure alone or in combination with a known
inducer of obesity and insulin resistance, such as high-fat diet, will exacerbate obesity and insulin
resistance symptoms in mice model. Thus, the current study was to determine if fipronil promotes
adipogenesis in 3T3-L1 adipocytes and if chronic exposure to low levels of imidacloprid promote
metabolic disorders characterized by adiposity, dyslipidemia, hyperglycemia, and insulin
resistance in high fat diet-induced C57BL/6J mice model.
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CHAPTER 2
LITERATURE REVIEW

2.1 Organic environmental pollutants introduction and classification
This chapter will focus on organic environmental pollutants, including persistent organic
pollutants (POPs), pesticides (not on POPs Stockholm Convention list), bisphenol A and
phthalates. POPs represent a diverse range of chemicals, which are persistent in the body and the
environment [10]. POPs bio-accumulate in animal and human with potentially significant impacts
on human health and the environment [10]. A wide variety of chemicals were included in the
POPs category, including organochlorine insecticides, polychlorinated biphenyls (PCBs), dioxinlike compounds, brominated flame retardants (BFRs), and perfluorinated compounds [10].
Organochlorine insecticides consist of DDT, dieldrin, heptachlor, chlordane, lindane, and
toxaphene, all of which have chlorinated hydrocarbon structures [11]. Organochlorine
insecticides have very low water solubility and very high lipid solubility [11], thus extremely
resistant to degradation and persistent in the environment [11]. Organochlorine insecticides are
mainly divided into two groups: DDT-type insecticides and chlorinated alicyclic insecticides. The
mechanism of insecticide action of DDT-type insecticides is by preventing the closing of sodium
gates of the axon, resulting in persistent leakage of Na+ ions through the nerve membrane and
repetitive firing of action potentials [11]. By comparison, chlorinated alicyclic insecticides is
purported to bind with gamma-aminobutyric acid (GABA) chloride ionophore complex, thus
resulting in hyper-excitation [11]. DDT was once one of the most popular insecticides used
against insects during 1940s to 1960s [12]. Dichlorodiphenyldichloroethylene (DDE), a major
metabolite of DDT, is also used as an insecticide. Due to their potential toxicity to plants, animals
and persistency in the environment, most developed countries including USA have banned the
use of DDT and other organochlorine insecticides in 1970s [12]. However, DDT and other
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organochloride residues continue to be found in humans and mammals many years after the use
have been limited and DDT is still used in sub-Saharan Africa and India to fight malaria [13, 14].
A polychlorinated biphenyl (PCB) is an organic chlorine compound with the formula
C12H10−xClx. PCBs were once widely used as dielectric and coolant fluids in electrical
apparatus and in heat transfer fluids [15]. PCBs consist of 209 isomers and congeners with
different numbers and positions of chlorine atoms substituted on the biphenyl moiety [15]. Some
PCBs share a structural similarity and toxic mode of action with dioxin through aryl hydrocarbon
(AH) receptor, which regulates the expression of many genes [16]. Other toxic effects such as
endocrine disruption (notably blocking of thyroid system functioning) and neurotoxicity are
known [17]. PCBs are persistent in the environment, bio-accumulate and bio-magnify in the food
chain, due to their lipophilicity [15]. Exposure to PCBs have been reported to induce biochemical
and morphological changes in cells and laboratory animals that are linked to neurological and
behavioral dysfunctions [15].
Dioxin-like compounds, including polychlorinated dibenzo-p-dioxins (PCDDs), 2,3,7,8tetrachlorodibenzodioxin (TCDD), polychlorinated dibenzofurans (PCDFs), mostly come from
by-products of industrial processes, such as bleaching paper pulp, pesticide manufacture, as well
as waste incineration [18, 19]. Dioxin-like compounds act through aryl hydrocarbon (AH)
receptor, which is present in all cells [20-23]. The receptor is a transcription factor involved in
expression of a variety of genes [20]. Low doses of dioxin-like compounds exposure have
developmental effects, such as palate and hydronephrosis [24].
Brominated flame retardants (BFRs), which have an inhibitory effect on combustion
chemistry, are widely used in global industry, and many of them are still produced and used in
large volumes [25]. Due to this, several BFRs are found in both wildlife as well as in humans [25].
Polybrominated diphenyl ethers (PBDEs), polybrominated biphenyl (PBB), and brominated
cyclohydrocarbons are three major types of BFRs [26]. Some PBDEs are lipophilic and bioaccumulate in fatty tissue and PBDEs have been detected in people all over the world [27].
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Perfluorinated compounds (PFC) are organofluorine compounds with carbon-fluorine
bonds, C-C bonds, and other heteroatoms. These fluorinated chemicals are used in various of
consumer goods from non-stick kitchenware to waterproof clothing [28]. Two PFCs,
perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), have been found to be
persistent and toxic, which pose a global contamination problem [29]. In animals, some PFCs can
disrupt normal endocrine activity, reduce immune function, and cause adverse effects on multiple
organs, including the liver and pancreas [30, 31].
Other insecticides, which are not included in the POPs categories, include pyrethroids,
organophosphorus insecticides, carbamates, and neonicotinoids in the current review. Pyrethroids
are synthetic compounds similar to the natural insecticide pyrethrins in the flowers pyrethrums
(Chrysanthemum cinerariaefolium and C. coccineum). Pyrethroids can prevent the closure of
voltage-gated sodium channels in axonal membranes, causing over-excitation of the neuron [12,
32]. Pyrethroids are developed in the 1960s and 1970s and are known to be effective against
insects with low mammalian toxicity. At present, 13 pyrethroids in more than 3,500 registered
formulations are widely used in the United States to control insect pests in agriculture, animal
protection, and public health [33].
Organophosphorus insecticides are the largest insecticide class in the world in 1980s,
occupying about 70% of world insecticides market in 1987. Organophosphorus insecticides
inactivate the enzyme acetylcholinesterase, causing over-excitation of the neurons [34]. However,
the use of organophosphorus insecticides is decreasing due to their environmental persistence [35,
36]. A carbamate is an organic compound derived from carbamic acid (NH2COOH) with
carbamate ester and carbamic acids as functional groups. Carbamates can also inhibit the enzyme
acetylcholinesterase (AChE), thus leading to over-excitation of the neurons, but the inhibition of
AChE is reversible and carbamates are rapidly metabolized in animals [37, 38].
Neonicotinoids are a relatively new class of insecticides with similar structure as nicotine.
Neonicotinoids are agonists to nicotinic acetylcholine receptors (nAChRs), which can stimulate
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these receptors at low dose, while block these receptors in high dose, leading to paralysis or death
[39]. They have high affinity for insect nAChRs, but not for vertebrate nicotinic acetylcholine
receptor, thus having selective toxicity for insects [40, 41]. Neonicotinoids are the fastest growing
class of insecticides, representing ~27% of the global insecticide market in 2010, making it the
largest single insecticide class on the market [42]. Imidacloprid and two other neonicotinoids
were banned by the European Commission in 2013 due to their potential risk for the decrease of
bee populations [43].
Bisphenol A (BPA) belongs to a group of phenols, which have hydroxyl residue bounded
to aromatic ring. BPA is used in various products for everyday use, including water-pipes,
electronic equipment, paper, as well as food packaging materials. It can bind to several kinds of
receptors, including estrogen, androgen, aryl hydrocarbon and peroxisome proliferator-activated
receptors that are related to endocrine and other systems of the body [44].
Phthalates are esters of phthalic acid and are mainly used as plasticizers. They are present
in a variety of products, including food packaging, building materials, clothing and medical
devices [45]. Phthalates are not covalently bounded to the plastic matrix, thus leaching out to the
external environment easily. Although most phthalates show very low-acute toxicity, the
reproductive system is susceptible to these compounds, thus European Union started to ban the
use of reproductive toxic phthalates in toys and childcare articles in 2005 [45].

2.2 Insulin resistance and type 2 diabetes
Obesity is now endemic and the prevalence of type 2 diabetes (T2D), which is closely
associated with obesity, is also on the rise [46]. Type 2 diabetes also known as non-insulin
dependent diabetes, is the most common form of diabetes [47]. Insulin resistance, a hallmark of
type 2 diabetes, is a pathological condition, in which cells fail to respond to insulin [48]. Insulin
resistance is associated with many factors, which include decreased expression or tyrosine
phosphorylation of insulin receptor and insulin receptor substrate, decreased expression or
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translocation of glucose transporters, and abnormal expression or activities of a variety of
enzymes [49].
Adipose tissue has a very important role in insulin resistance. Circulating free fatty acids
(FFA) obtained from adipocytes have been suggested to promote insulin resistance by inhibiting
insulin signaling, glucose uptake, glycogen synthesis, and glucose oxidation, as well as by
elevating hepatic glucose output [50]. Studies also revealed that diacylglycerol and ceramides
accumulation in muscle and liver can activate Novel protein kinase C Isoforms (nPKCs), thus
causing insulin resistance [46]. Overexpression of hepatic lipoprotein lipase or fatty acid
translocase (CD36) promotes hepatic lipid accumulation and can lead to insulin resistance [46].
Adipose tissue also produces and secretes adipokines, which may significantly affect
lipid and glucose metabolism as well as energy expenditure. Compared to lean subjects, in obese
rodents and humans, tumor-necrosis factor-α (TNF- α) expression is increased and has been
reported to induce serine phosphorylation of IRS-1, resulting in reduced insulin receptor kinase
activity and insulin responsiveness [51]. The mRNA expression of adiponectin, another adipokine
secreted by adipose tissue that sensitize insulin responses, is also decreased in obese humans and
mice [52]. Acute treatment of mice with this adipokine alleviates insulin resistance, decreases
plasma FFAs and triglycerides content of muscle and liver, as well as increases expression of
genes involved in fatty-acid oxidation and energy expenditure [52]. In addition, leptin produced
by adipose tissue acts on its receptors in the central nervous system and other tissues to regulate
food intake and energy expenditure [53]. Leptin deficiency or resistance are known to link insulin
resistance, as proven by administration of exogenous leptin improves glucose tolerance and
insulin sensitivity [53-55].

2.3 Persistent organic pollutants (POP) and type 2 diabetes
Numerous studies have reported the potential association between POP exposure and impaired
glucose metabolism or type 2 diabetes (summarized in Table 2.1). In one study, adipose tissue
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concentrations of POPs were suggested to provide a suitable estimation of cumulative internal
exposure to POPs, while serum concentrations of POPs might be a good predictor of point
exposure [56]. There were a number of publications linking 2,2-bis (4-chlorophenyl) -1,1dichloroethylene (p,p'-DDE), 2,2-bis (4-chlorophenyl)-1,1-dichloroethane (p,p'-DDD), two
metabolites of 2,2-bis (4-chlorophenyl)-1,1,1-trichloro-ethane (p,p'-DDT) and increased risk of
diabetes [5, 56-75]. However other studies didn’t find the association between DDE exposure and
risk of diabetes [76-83]. Two studies reported increased plasma DDE concentrations in diabetic
individuals than no-diabetic individuals, however, they failed to prove significant association
between DDE and diabetes [76, 77]. It was suggested that the higher plasma level of DDE might
be due to greater lipolysis rate in diabetic individuals compared to non-diabetic individuals [76,
77].
Similarly, DDT was related to increased risk of diabetes in several human studies [58, 6062, 67-69, 84, 85]. Two studies reported that low-dose background exposure of DDT was
strongly associated with the prevalence of type 2 diabetes in Asia, which suggested that Asians
might be more susceptible to adverse effects of DDT than other races [60, 62]. Serum
concentrations of POPs, including DDT, were further related to decreased glucose utilization and
higher lipid oxidation in non-diabetic individuals and the prevalence of prediabetes and diabetes
in Eastern Slovakia [67].
Several studies reported the potential link between hexachlorobenzene (HCB) and
diabetes [60, 63, 67, 69, 70, 77, 81, 83]. One prospective study reported that childhood (8-9 years
old) HCB exposure was associated with higher odds of insulin resistance when measured at 10-13
years old [81]. Although one study reported positive correlation between adipose tissue HCB and
diabetes [56], other studies didn’t find the significant association between HCB exposure and
diabetes [5, 56, 58, 76, 79].
β-Hexachlorocyclohexane (β-HCH) was reported to be associated with insulin resistance
or diabetes in many studies [56, 58, 60, 61, 68, 81, 86], while others reported no significant
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association of β-HCH with diabetes or insulin resistance [5, 67, 76, 77, 79, 83, 87, 88]. Similarly,
γ-hexachlorocyclohexane (γ-HCH) was reported to be positively associated with diabetes in one
study [89], but not others [5, 79].
Chlordane and its metabolite oxychlordane as well as trans-nnonachlor were linked to
increased risk of diabetes [58, 60, 61, 74, 79, 85, 87, 90, 91]. However, the other studies didn’t
support these potential linkages [5, 76, 78, 83, 88]. Similarly, there are limited human studies
reported the association between heptachlor, heptachlor epoxide (a metabolite of heptachlor),
mirex or aldrin and increased risk of diabetes [60, 61, 63, 79, 82, 92, 93], although three studies
didn’t support the association of mirex or aldrin with diabetes [5, 61, 76].
Polychlorinated biphenyls (PCB) were intensively studied and reported to be associated
with increased risk of diabetes [56, 57, 63, 65, 66, 69, 70, 73, 74, 77, 79, 90, 94-97], while others
reported no association between PCBs and diabetes [76, 78, 80, 86, 98, 99]. Dioxins, including
hexachlorodibenzo-p-dioxin

(HxCDD),

1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin

2,3,7,8-Tetrachlorodibenzo-p-dioxin
(HpCDD)

and

polychlorinated

(TCDD),

dibenzodioxins

(PCDDs) were suggested to be positively associated with risk of diabetes in a few studies [74,
100, 101]. While no association was reported between HxCDD and risk of diabetes in one study
[86].
Some studies reported a positive association between polybrominated diphenyl ethers
(PBDEs) and diabetes [73, 102], while another study didn’t find such positive association [76].
Polybrominated biphenyls (PBBs) were reported to be positively associated with diabetes [79,
102], but not in the other study [5]. 2,2’,4,4’-tetrabromodiphenyl ether (BDE 47), 2,2’,4,4’,5,5’hexabromodiphenyl ether (BDE153) or perfluoroalkyl substances were nor found to have positive
relationship with risk of diabetes [78, 80, 90].
As shown in Table 2.1, it may be sufficient to conclude for a positive correlation between
certain POPs exposure and risk of diabetes, especially for DDT, DDE, HCB and PCB. However,
most of these are cross-sectional studies, which have their limitation in establishing a clear causal
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relationship. Thus, more prospective human studies are needed to clarify the causal relationship
between POPs exposure and diabetes.
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Table 2.1. Summary of epidemiological and clinical studies of persistent organic pollutants
(POP) on risk of diabetes in human.
Subject
Study design
Description

Gender

Risk of
diabetes

Other comments

Ref.

Organochlorines
2,2-bis (4-chlorophenyl)-1,1-dichloroethylene (p,p'-DDE)
Case-control

Sweden

F

×

[83]

Cross-section

Sweden

F+M

↑

[75]

Cross-section

USA

F+M

↑

[74]

Cross-section

USA
Native Americans
USA
Mexican
Americans
USA

F+M

↑

[63]

F+M

↑

[58]

F+M

↑

[88]

F

↑

Self-reported

[66]

F+M

↑

Self-reported

[57]

F

↑

[64]

F+M

↑

[72]

Cross-section

Sweden
Fishermen’s wives
Canada
First nation
community
Sweden
50-59 old women
USA, Great Lakes
sport fish
consumers
USA

F+M

↑

[61]

Case-control

USA

F+M

×

[79]

Case-control

Korea

F+M

↑

Cross-section

Slovak Republic

F+M

↑

[67]

Prospective

USA

F+M

↑

[5]

Prospective

F+M

×

[80]

Cross-section

Sweden, 70 yearsold
Denmark

F+M

↑

Cross-section

Spain

F+M

×

[77]

Cross-section

Spain

F+M

↑

[56]

Cross-section

Canada
First nation

F+M

×

Cross-section

Cross-section
Cohort
Cross-section

Case-control
Prospective
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Self-reported

↑ Lipid oxidation
↓ Glucose
oxidation

↑ Blood DDE in
diabetic

[60]

[69]

[76]

community
Case-control

Benin

F+M

↑

↑ Blood DDE

[68]

Prospective

Russia

M

×

↓ Leptin

[81]

Cross-section

Belgium

F+M

↑

[65]

Cross-section

Slovakia

F+M

↑

[71]

Cross-section

Thailand

F+M

↑

[59]

Cross-section

Saudi Arabia

F+M

↑

Prospective

F+M

↑

Prospective

USA, Great Lakes
sport fish
consumers
Belgium

F+M

↑

Only in M

[70]

Cohort

France, Newborns

F+M

×

↓ insulin
↓ adiponectin

[82]

Cohort

Canada

F

×

↑ Insulin

[62]
[73]

[78]

2,2-bis (4-chlorophenyl)-1,1,1-trichloro-ethane (p,p'-DDT)
F+M

↑

Cross-section

USA
Mexican
Americans
USA

F+M

↑

[84]

Cross-section

USA

F+M

×

[87]

Cross-section

USA

F+M

↑

[61]

Cross-section

USA

F+M

×

[79]

Case-control

Korea

F+M

↑

[60]

Cross-section

Slovak Republic

F+M

↑

[67]

Prospective

USA

F+M

×

[5]

Cross-section

Denmark

F+M

↑

Cross-section

Spain

F+M

×

Case-control

Benin

F+M

↑

Cross-section

Korea

F+M

↑

Cross-section

Saudi Arabia

F+M

↑

Cross-section

Self-reported

↓ Glucose
oxidation

[58]

[69]
[77]

↑ Blood DDT

[68]
[85]

↑ TG

[62]

2,2-bis (4-chlorophenyl)-1,1-dichloroethane (p,p'-DDD)
Case-control

Korea

F+M

2,2-bis(o,p-chlorophenyl)-1,1,1-trichloroethane (o,p'-DDT)
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↑

[60]

Case-control

Korea

F+M

↑

[60]

2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1,1-trichloroethane; hexachlorobenzene (HCB)
Case-control

Sweden

F

↑

Cross-section

F+M

×

F+M

↑

[63]

Cross-section

USA
Mexican
Americans
USA
Native Americans
USA

F+M

×

[79]

Case-control

Korea

F+M

↑

[60]

Cross-section

Slovak Republic

F+M

↑

[67]

Cross-section

Denmark

F+M

↑

Prospective

USA

F+M

×

[5]

Cross-section

Spain

F+M

↑

[77]

Cross-section

Spain

F+M

×

[56]

Cross-section

F+M

×

Prospective

Canada
First nation
community
Russia

M

↑

[81]

Prospective

Belgium

F+M

↑

[70]

[83]

Cross-section

[83]
Self-reported

↓ Glucose
oxidation

↑ Blood HCB

[58]

[69]

[76]

β-Hexachlorocyclohexane (β-HCH)
Case-control

Sweden

F

×

Cross-section

F+M

↑

Cross-section

USA
Mexican
Americans
USA

F+M

×

[88]

Cross-section

USA

F+M

×

[87]

Cross-section

USA

F+M

↑

[61]

Case-control

USA

F+M

×

[79]

Case-control

Korea

F+M

↑

[60]

Cross-section

Slovak Republic

F+M

×

[67]

Cross-section

Belgium

F+M

↑

[86]

Prospective

USA

F+M

×

[5]

Cross-section

Spain

F+M

×

[77]
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Self-reported

[58]

Cross-section

Spain

F+M

↑

Cross-section

F+M

×

↑ Blood β-HCH

[76]

Case-control

Canada
First nation
community
Benin

F+M

↑

↑ Blood β-HCH

[68]

Cross-section

Saudi Arabia

F+M

↑

[89]

Prospective

Russia

M

↑

[81]

[56]

ɣ-Hexachlorocyclohexane (ɣ-HCH)
Case-control

USA

F+M

×

[79]

Prospective

USA

F+M

×

[5]

Cross-section

Saudi Arabia

F+M

↑

[89]

Chlordane & oxychlordane
Case-control

Sweden

F

×

[83]

Cross-section

USA

F+M

↑

[74]

Cross-section

F+M

↑

Cross-section

USA
Mexican
Americans
USA

F+M

×

[88]

Cross-section

USA

F+M

↑

[87]

Prospective

F+M

↑

[91]

Cross-section

USA, pesticide
applicators and
spouses
USA

F+M

↑

[61]

Case-control

USA

F+M

↑

[79]

Case-control

Korea

F+M

↑

[60]

Cross-section

Finland
Helsinki Birth
Cohort
USA

F+M

↑

[90]

F+M

×

[5]

Canada
First nation
community
Canada

F+M

×

F

×

[78]

Case-control

Sweden

F

×

[83]

Cross-section

USA

F+M

↑

[74]

Prospective
Cross-section

Cohort

Self-reported

↑ Oxychlordane
in diabetic

[58]

[76]

Trans-nonachlor
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F+M

↑

Cross-section

USA
Mexican
Americans
USA

F+M

×

[88]

Cross-section

USA

F+M

↑

[87]

Cross-section

USA

F+M

↑

[61]

Cross-section

USA

F+M

↑

[79]

Case-control

Korea

F+M

↑

[60]

Prospective

USA

F+M

×

[5]

Heptachlor
epoxide
Cross-section

USA

F+M

↑

[61]

Cross-section

USA

F+M

↑

[92]

Case-control

Korea

F+M

↑

[60]

Cross-section

Korea

F+M

↑

[85]

Case-control

Korea

F+M

×

[93]

USA, pesticide
applicators and
spouses

F+M

↑

[91]

F+M

↓

[63]

Cross-section

USA
Native Americans
USA

F+M

×

[61]

Case-control

USA

F+M

↑

[79]

Case-control

Korea

F+M

↑

[60]

Prospective

USA

F+M

×

[5]

Cross-section

Canada
First nation
community

F+M

×

USA, pesticide
applicators and
spouses
Polychlorinated biphenyls (PCBs)

F+M

↑

[91]

Cross-section

F+M

↑

[74]

Cross-section

Self-reported

[58]

Heptachlor
Prospective

Mirex
Cross-section

↑ Blood mirex

[76]

Aldrin
Prospective

USA
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F+M

↑

[63]

Cross-section

USA
Native Americans
USA

F+M

↑

[84]

Cross-section

USA

F+M

↑

[94]

Cross-section

USA

F+M

↑

[87]

Cohort

F

↑

Cross-section

Sweden
Fishermen’s wives
Denmark

F+M

×

Prospective

Taiwan

F+M

↑

only in women

[96]

Exploratory

F+M

↑

Self-reported

[57]

Case-control

Canada
First nation
community
USA

F+M

↑

[79]

Cross-section

USA

F+M

↑

[92]

Cross-section

Finland
Helsinki Birth
Cohort
Belgium

F+M

↑

[90]

F+M

×

[86]

F+M

×

[80]

Cross-section

Sweden, 70 yearsold
Japan

F+M

↑

PCB 146 & 180

[98]

Cross-section

Japan

F+M

↓

[98]

Cross-section

Denmark

F+M

↑

PCB 163,164 &
170
↓ Glucose
oxidation

Cross-section

Spain

F+M

↑

[77]

Cross-section

Spain

F+M

↑

[56]

Cross-section

F+M

×

Cross-section

Canada
First nation
community
Belgium

F+M

↑

[65]

Cross-section

USA

F+M

↑

[95]

Cross-section

Korea

F+M

↑

[85]

Cross-section

Korea

F+M

↑

Case-control

USA

F+M

↑

[97]

Prospective

USA, Great Lakes
sport fish
consumers
Belgium

F+M

↑

[73]

F+M

↑

[70]

Cross-section

Cross-section
Prospective

Prospective
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Self-reported

[66]
[99]

↑ Blood PCBs in
diabetic

↓ Adiponectin

[69]

[76]

[103]

Cohort

Canada

F

×

[78]

Dioxin
Hexachlorodibenzo-p-dioxin (HxCDD)
Cross-section

USA

F+M

×

[84]

Cross-section

Taiwan

F+M

↑

[100]

USA, Vietnam
F+M
veterans
1,2,3,4,6,7,8-Heptachlorodibenzo-p-dioxin (HpCDD)

↑

[101]

Cross-section

↑

[74]

F+M

↑

[74]

F+M

↑

[74]

F+M

↑

[102]

Canada
First nation
community
Prospective
USA, Great Lakes
sport fish
consumers
Polybrominated biphenyl (PBB)

F+M

×

F+M

↑

[73]

Cross-section

USA

F+M

↑

[102]

Case-control

USA

F+M

↑

[79]

Prospective

USA

F+M

×

[5]

F+M

×

[90]

F+M

×

[80]

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)
Prospective

USA

F+M

1,2,3,4,6,7,8,9-Octachlorodibenzo-p-dioxin (OCDD)
Cross-section

USA

Polychlorinated dibenzodioxins (PCDDs)
Cross-section

USA

Brominated flame retardants (BFRs)
Polybrominated diphenyl ethers (PBDEs)
Cross-section

USA

Cross-section

↑ Blood PBDE47
in diabetic

[76]

2,2',4,4'-Tetrabromodiphenyl ether (BDE)
Cross-section

Finland
Helsinki Birth
Cohort
Prospective
Sweden, 70 yearsold
Perfluorinated compound (PFC)
Perfluorooctanoic acid (PFOA)
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Cohort

Canada

F

×

[78]

F

×

[78]

F

×

[78]

Perfluorooctane sulfonate (PFOS)
Cohort

Canada

Perfluorohexane sulfonate (PFHxS)
Cohort

Canada

F, female; M, male; TG, triglyceride.
↑, increase; ×, no association.

2.4 Other pesticides and impaired glucose metabolism
Compared to the large amount (> 70) of human studies about the influence of POPs on
impaired glucose metabolism, the studies of other pesticides-that’s not considered as POPs, on
impaired glucose metabolism are relatively limited (summarized in Table 2.2). In general,
subjects with pyrethroid exposure tend to have higher prevalence of abnormal glucose regulation,
which might have implications in the development of type 2 diabetes. Two studies reported the
positive associations of pyrethroid occupational exposures and abnormal glucose regulation [104,
105]. A paper in 2008 reported that two pyrethroids (allethrin and prallethrin) exposure by
inhalation significantly elevated the plasma glucose levels in exposed subjects [106]. There is a
case report of hyperglycemia after intravenously injection of an unknown amount of a mixture of
chlorpyrifos and cypermethrin [107].

However, others didn’t find significant effects of

permethrin on ‘self-reported diabetes’, which is the limitation of the study [91].
Several studies reported the potential correlation between organophosphorous and
impaired glucose metabolism, which is summarized in Table 2.2. Farmers and their families were
reported to have hyperglycemia or higher HOMA-IR after exposure to malathion [108-111]. One
study reported that exposure to parathion, malathion, and diazinon was associated with
pancreatitis accompanied with hyperglycemia [111]. A 15-year old girl who intentionally
consumed overdose of unspecified organophosphorous pesticide was found to have elevated
glucose level as high as 336 mg/dl [112]. Another cohort study reported that urinary
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dialkylphosphate metabolites of organophosphate pesticides were associated with increased
insulin levels, though insulin resistance was not linked to dialkylphosphate metabolites of
organophosphorous [82]. However, others didn’t find the association of other organophosphorous
and diabetes, such as reverse associations with gestational diabetes mellitus and impaired glucose
tolerance during pregnancy [78].
Overall, there are human studies linking pesticides exposure to diabetes, which are shown
in Table 2.2, but more human studies, especially prospective studies, are still needed to find the
causal relationship. More animal studies can also be a valuable tool to understand the underlying
mechanisms between these pesticides and diabetes.
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Table 2.2. Summary of human studies of other pesticides on risk of diabetes.
Subject
Study design
Description

Gender

Risk of
diabetes

Other
comments

Ref.

Pyrethroids
Allethrin & prallethrin
Controlled trial

India

M

N/A

↑ Glucose

[106]

USA
Pesticide applicators

F+M

N/A

Self-reported

[91]

China
Pesticide applicators

F+M

↑

↑ BMI

[104]

M

↑

M

N/A

↑ Glucose

[107]

F+M

N/A

↑ Glucose

[108]

Permethrin
Prospective
Mixture
Case-control

α-Cypermethrin & λ-cyhalothrin
Cross-section

Bolivia
Pesticide applicators

[105]

Chlorpyrifos & cypermethrin
Case report

Morocco

Organophosphorus
Malathion
Case report
Cross-section
Cross-section

Canada
A woman and her
son
UDA, wives of
farmers
Egypt, farmers

F

×

M

↑

[113]
↑ Insulin

[109]

Acute
pancreatitis
↑ Glucose

[111]

Parathion, malathion & diazinon
Prospective

Israel, children

F+M

Cross-section

USA

F

UDA, wives of
farmers

F

N/A
↑

[113]

Diazinon & phorate
Cross-section

[113]

Unspecified &mixrure
Cross-section

Turkey

F+M

N/A

↑ Glucose

[114]

Cross-section

Iran, farmers

F+M

↑

↑ Glucose

[110]
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Case report

India

F

N/A

↑ Glucose

[112]

Cohort

France, newborns

F+M

N/A

↑ Insulin

[82]

N/A

Inverse
association
with glucose
tolerance

[78]

Cohort

Canada

F

Dichlorvos & trichlorfon
Prospective

USA
Pesticide applicators

F+M

↑

[91]

USA, wives of
farmers

F

×

[113]

Israel, children

F+M

N/A

[111]

× Carbaryl
↑ Carbofuran

[113]

Turbufos
Cross-section
Carbamates
Unspecified
Prospective

Carbaryl & carbofuran
Cross-section

USA, wives of
farmers

F

F, female; M, male.
↑, increase; ×, no association; N/A, not applicable.

20

2.5 Bisphenol A (BPA) and diabetes
BPA has been reported to be positively associated with diabetes, which are summarized
in Table 2.3. Positive association of urinary BPA with diabetes based on US National Health and
Nutrition Examination Survey (NHANES) was reported in five studies [115-119], in particular,
the association between BPA and prediabetes was stronger in obese people [117]. It is important
to point out that individuals with higher BMI, who are more likely to have diabetes, might also
have higher consumption of food contaminated with BPA, thus, might having higher levels of
BPA [117]. Similarly, it was also suggested that higher level of BPA could potentially be linked
to sugar beverages in plastic bottles and intake of sugar beverages might have complications in
obesity and diabetes [120]. However, there are three studies not supporting the association of
BPA with diabetes [121-124], including no positive association of BPA exposure during
pregnancy and gestational diabetes [122, 123], although the studies have a limited sample size or
the urinary BPA concentration was substantially lower than other pregnancy cohort. In summary,
it is highly likely that there is a positive relationship between BPA and diabetes. However,
several questions, including whether sugar beverages, BPA, or their interaction are the main
causes of increased risk of diabetes, need to be answered.
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Table 2.3. Summary of human studies of bisphenol A on risk of diabetes.
Subject
Study design

Risk of diabetes Other comments

Ref.

Description

Gender

Cross-section

USA

F+M

↑

[115]

Cross-section

China

F+M

×

[124]

Cross-section

USA

F+M

↑

[116]

Cross-section

USA

F+M

↑

[119]

Cross-section

China

F+M

↑

[120]

Cross-section

Korea

F+M

×

[121]

Prospective

USA

F

↑

[125]

Case-control

USA

F+M

×

Cross-section

USA

F+M

↑

Cross-section

USA

F+M

↑

Prospective

USA, nurses

F

↑

[126]

Cross-section

Thai

F+M

↑

[127]

Cross-section

Italy

F+M

↑

[128]

Prospective

Canada

F

×

[122]

Prospective

China

F+M

↑

[129]

Cross-section

Canada

F+M

↑ only in M

[130]

F, female; M, male.
↑, increase; ×, no association.
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During pregnancy

[123]
[117]

Stronger link in M

[118]

2.6 Phthalates and diabetes
Phthalates were positively associated with diabetes in many studies and are summarized
in Table 2.4. Several cross-sectional studies in the USA reported positive association between
phthalates exposure and increased risk of diabetes [126, 131-138], while two studies reported no
association of phthalates with risk of diabetes [122, 139]. It was suggested that diethylhexyl
phthalates (DEHP) caused diabetes is related to oxidative stress [140]. Another study suggested
that Mexican Americans and non-Hispanic Blacks might be more susceptible to phthalates
induced disturbances in glucose homeostasis than non-Hispanic Whites [136]. HSP70-hom gene
polymorphisms was also reported to contribute to the association of DEHP with insulin resistance
[137]. However, another study observed negative association between urinary phthalate
concentrations and blood glucose level [139]. Overall the human study about phthalates and
diabetes is still very limited and more studies are needed before any conclusion can be made.

2.7 Conclusion
Accumulating evidence are supporting the positive role of environmental pollutants in
risk of diabetes, including some organochlorine, organophosphorous pesticides, HCB, PCB with
less studies on carbamates, pyrethroids and neonicotinoids. However, there is still relatively small
number of prospective studies, thus making it difficult to make firm conclusions. Questions
including dose-response relationship and the mechanisms how the glucose metabolism is
impaired by environmental pollutants still need to be answered. Thus, more prospective human
studies are needed to confirm the results. It is also important to investigate the effects and the
underlying mechanisms of these environmental pollutants on alteration of glucose and lipid
metabolism in vitro and in vivo.
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Table 2.4. Summary of human studies of phthalate on risk of diabetes.
Subject
Study design

Risk of
diabetes

Other comments

Ref.

↑ Obesity

[131]

Description

Gender

Cross-section

USA

M

↑

Cross-section

F

↑

[132]

Cross-section

USA
Lactating women
USA, elderly

F+M

↑

[133]

Cross-section

USA

F

↑

[134]

Cross-section

USA, adolescents

F+M

↑

[135]

Cross-section

Korea

F+M

↑

↑ Oxidative stress

[140]

Cross-section

USA

F

↑

[136]

Cross-section

USA

F

↑

Stronger in
Mexican
Americans & nonHispanic Blacks
Role of HSP70hom gene
polymorphisms

Prospective

USA, nurses

F

↑

[126]

Cross-section

Belgium, obese

F+M

↑

[138]

Cross-section

USA, pregnant

F

×

Phthalate

↑ Glucose

[137]

[139]

Di-isononyl phthalate (DINP) & di-isodecyl phthalate (DIDP)
Cross-section

USA, adolescents

F+M

↑

[141]

Prospective

Canada

F

×

[122]

F, female; M, male.
↑, increase; ×, no association.
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CHAPTER 3
FIPRONIL PROMOTES ADIPOGENESIS VIA AMPKα-MEDIATED PATHWAY IN
3T3-L1 ADIPOCYTES

3.1 Introduction
Fipronil

(5-amino-1-[2,

6-dichloro-4-(trifluoromethyl)

phenyl]-4-[(trifluoromethyl)

sulfinyl]-1H-pyrazole-3-carbonitrile) is one of the important broad spectrum insecticides used for
the control of arthropod pests, which threaten agricultural yields and the health of humans and
other animal species [142]. As a phenylpyrazole compound, fipronil’s action is attributable to the
potent, antagonistic action at the neurotransmitter gamma-aminobutyric acid (GABA) receptor. In
addition, fipronil disrupts the insect nervous system by blocking both GABA-gated chloride and
glutamate-gated chloride (GluCl) channels [143]. Given that fipronil has a higher binding affinity
to insect GABA receptors, and mammals do not have glutamate-gated chloride channels, fipronil
has a selective toxicity towards insects compared to mammals [144, 145].
Fipronil is known to be degraded in the environment through photolysis, oxidation, and
reduction. It is reported that fipronil is more susceptible to photolysis (half life, ~8 hr) than
hydrolysis (half life, > 100 days) in water at pH 5 [146]. Interestingly, desulfinyl fipronil, a
primary photolysis product of fipronil, has approximately 10-fold higher affinity for mammalian
GABA receptors than the parent fipronil and substantially reduces selectivity between insects and
mammals [145]. As fipronil has been formulated into a variety of products, such as solid insect
baits, liquid sprays, and a granular products, it has been used to control a broad range of
arthropod pests, including the boll weevil, grasshoppers, plant hoppers, ants, cockroaches,
termites, fleas and ticks [147]. This wide range of usage makes animal and human exposure to
fipronil nearly unavoidable [148]. Pesticides ingestion are potential risks for metabolic disorders,
and fipronil is listed as risk level 3, which needs to be particularly monitored in food [149]. Based
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on previous publications on the relationships between exposure to insecticides and obesity,
including our previous reports of other types of insecticides promoting adipogenesis in 3T3-L1
adipocytes [4-7, 150-153], we presently determine the role of fipronil in adipogenesis using the
3T3-L1 adipocyte model.

3.2 Materials and Methods
3.2.1 Materials
3T3-L1 preadipocytes were obtained from American Type Culture Collection (Manassas,
VA). Fetal bovine serum (FBS), Dulbecco’s modified Eagle’s medium (DMEM),
methylisobutylxanthin, insulin, dexamethasone, dimethyl sulfoxide (DMSO), 5-aminoimidazole4-carboxamide ribonucleotide (AICAR), and fipronil were purchased from Sigma-Aldrich Co.
(St. Louis, MO). The contents of triglyceride and protein were quantified using kits from Thermo
Scientifics (Middletown, VA) and Bio-Rad Co. (Hercules, CA), respectively. Trizol was bought
from Thermo Scientific (Rockford, IL) and other chemicals were purchased from Fisher
Scientific (Pittsburgh, PA). Radioimmunoprecipitation assay (RIPA) buffer supplemented with
1% protease inhibitor was purchased from Boston Bioproducts Inc. (Ashland, MA).

3.2.2 3T3-L1 Culture
3T3-L1 preadipocytes were cultured as described in a previous paper [7]. 3T3-L1
preadipocytes were maintained in DMEM with 10% FBS at 37 °C until confluence. 2 days after
confluence (day 0), adipocyte differentiation was induced with DMEM containing 10% FBS and
a mixture of methylisobutylxanthin (0.5 mM), dexamethasone (1 μM), and insulin (1 μg/mL). On
day 2, the medium was changed to DMEM containing 10% FBS and insulin only. From day 4,
cells were maintained in DMEM plus 10% FBS, and the medium was changed at 2-day intervals.
Cells were treated with fipronil (0.1, 1, and 10 µM) or 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR) (40 µM) from day 0 as indicated in each figure legend. Fipronil (100
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mM) and AICAR (0.4 M) stock solutions were prepared in DMSO. Control was treated with
DMSO and all treatments had DMSO at a final concentration of 0.02%. We didn’t observe any
influences of these concentrations of fipronil on cell viability measured by a 3-(4,5dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) based assay method as previously
described [154] (data not shown).

3.2.3 Triglyceride quantification
Cells were washed with phosphate-buffered saline (PBS) and harvested by scraping in
PBS containing 1% Triton-X after 8 days of differentiation. Homogenous samples were obtained
from cells by sonication. The amount of triglyceride (TG) in the samples was measured with a
commercial assay kit (Infinity™ Triglycerides Reagent; Thermo Scientific) and the protein
content was measured with Bio-Rad DC protein assay kit according to manufacturer’s
instructions. TG content was normalized with protein concentration.

3.2.4 mRNA expression analysis
Trizol reagent was used to extract total RNA from cells under RNase free conditions.
Total RNA was reverse-transcribed with Moloney murine leukemia virus (M-MLV) reverse
transcriptase (high-capacity reverse transcription kit, Applied Biosystems). mRNA expression
levels of CCAAT/enhancer-binding protein α (C/EBPα), peroxisome proliferator-activated
receptor gamma (PPAR-γ), acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), fatty acid
binding protein 4 (FABP4), adipose triglyceride lipase (ATGL), glucose transporter 4 (GLUT4),
and leptin were analyzed from 3T3-L1 adipocytes. Real-time polymerase chain reaction (PCR)
was performed on a StepOne Plus real time PCR instrument (Applied Biosystems, Carlsbad, CA)
and Taqman probe-based gene expression analysis (Applied Biosystems, Carlsbad, CA).
Respective integrated sequences for Taqman gene expression were NM_007678.3 (C/EBPα),
NM_001127330.2 (PPAR-γ), NM_133360.2, NM_007988.3 (FAS), NM_024406.2 (FABP4),
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NM_001163689 (ATGL), NM_009204.2 (GLUT4), and NM_008493.3 (leptin), with
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, NM_008084.2) as an internal standard.

3.2.5 Immunoblotting
Cells were lysed with RIPA buffer supplemented with phosphatase inhibitor cocktail and
protease inhibitor cocktail (Thermo Scientific, Rockford, IL). Protein concentrations were
determined using the protein DC assay kit (Bio-Rad Co., Hercules, CA). Cell lysates containing
50 μg of protein were separated with 6% or 10 % SDS-polyacrylamide gel and transferred to
Immobilin P membrane (Millipore, Bedford, MA). Primary rabbit antibodies were diluted
following the recommendation of producers. β-actin was used as an internal control. Horseradish
peroxidase conjugated goat anti-rabbit IgG was used as the secondary antibody. Detections were
performed on an image Station 4000MM (Carestream Health, New Haven, CT) with ClarityTM
Western ECL Substrate Kit (Bio-Rad Co., Hercules, CA). Image and results were quantified with
Image J software [155].

3.2.6 Statistical analyses
Data were analyzed by the analysis of variance procedure (ANOVA) using the Statistical
Analysis System (SAS Institute, Cary, NC). Tukey’s multiple-range test was used to determine
significant differences between treatments. Significance of differences was defined at the P<0.05
level.

3.3 Results
3.3.1 Triglyceride measurements in 3T3-L1 adipocytes
Fig. 3.1 shows effects of fipronil on lipid accumulation in 3T3-L1 adipocytes. Fipronil
(10 M) treatment significantly increased TG content, compared to control, but not at lower
concentrations, in this model.
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3.3.2 Influence of fipronil on genes controlling adipocyte differentiation and lipid
metabolism
Treatment with fipronil (10 M) significantly increased expression of two key genes
involved in adipocyte differentiation, CCAAT/enhancer-binding protein α (C/EBPα) and
peroxisome-proliferator activated receptor-γ (PPARγ), compared to control (Fig. 3.2A and 3.2B).
Fipronil (10 M) also significantly increased expression of two rate limiting enzymes for
lipogenesis, fatty acid synthase (FAS) and acetyl Co-A carboxylase (ACC) (Fig. 3.2C and 3.2D),
compared to control. Expression of fatty acid-binding protein 4 (FABP4), a protein transporting
fatty acids in cytoplasm for metabolic process or storage [156] was likewise increased
significantly by 10 M fipronil treatment compared to control (Fig. 3.2E). These results show that
fipronil promoted adipocyte differentiation and lipogenesis, contributing to increased lipid
accumulation at 10 M.
Expression of glucose transporter 4 (GLUT4), a 12 transmembrane protein that plays a
major role in insulin mediated glucose transport in adipocytes [157], was also significantly
increased following 10 M fipronil treatment compared to control (Fig. 3.2F). This finding
suggests that fipronil may have altered glucose metabolism, which also contributes to increased
lipid accumulation in this model. Fipronil treatment, up to 10 M, did not affect expression of
leptin and adipose triglyceride lipase (ATGL) (Fig. 3.2G and 3.2H), which are known to correlate
with obesity [158, 159].
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Figure 3.1. Fipronil treatment increased triglyceride accumulation in 3T3-L1 adipocytes. Cells
were treated with fipronil for 8 days. Each value is expressed as the mean ± standard error of 3
independent experiments (n=10-12). Means with different letters were significantly different at
P<0.05.
3.3.3 Effects of fipronil on the protein expression of regulators controlling adipogenesis
We further investigated the influence of fipronil on the protein expression of key
regulators of adipogenesis (Fig. 3.3). Compared to control, fipronil (10 M) treatment
significantly increased the protein expression of C/EBPα and PPAR (Fig. 3.3B and 3.3C).
AMPKα is a master regulator of energy production and lipid metabolism in the cell [160].
Fipronil (10 M) treatment decreased the phosphorylation of AMPKα significantly compared to
control, without affecting the total levels of AMPKα (Fig. 3.3D, 3.3E and 3.3F). These results
indicate reduced activation of AMPKα by fipronil. Expression of ACC (active form), a
downstream target of AMPKα, was increased significantly, while phosphorylation of ACC
(inactive form) was decreased significantly by fipronil treatment compared to control (Fig. 3.3G,
3.3H and 3.3I).
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Figure 3.2. Effects of fipronil on gene expression of molecular mediators of adipogenesis.
C/EBP-α, CAATT element binding protein-α; PPARϒ, Peroxisome proliferator-activated
receptor gamma; FAS, Fatty acid synthase; ACC, Acetyl-CoA carboxylase; FABP4, Fatty acid
binding protein 4; GLUT4, Glucose transporter type 4; HSL, Hormone-sensitive lipase; LPL,
Lipoprotein lipase; ATGL, Adipose triglyceride lipase. Numbers represent mean ± S.E. (n=4-6).
Means with different letters were significantly different at P<0.05.
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Figure 3.3. Effects of fipronil on protein levels of molecular mediators of adipogenesis. C/EBP-α,
CAATT element binding protein-α; PPAR-γ, peroxisome proliferator-activated receptor-γ;
AMPKα , AMP-activated protein kinase-α (inactive form); pAMPKα, phosphorylated AMPKα
(active form), ACC, acetyl-CoA carboxylase (active form); pACC, phosphorylated ACC (inactive
form). Cells were treated with fipronil for 8 days. Numbers represent mean ± S.E. (n=3). Means
with different letters were significantly different at P<0.05.
3.3.4 Effect of AMPKα activation on adipogenesis induced by fipronil
We next investigated whether AMPKα activation could inhibit enhanced adipogenesis
induced by fipronil. An AMPK activator, 5-amino-4-imidazolecarboxamide riboside-1-β-Dribofuranoside (AICAR) is an adenosine analogue, which is taken up by adenosine transporters
on the cell membrane and then is phosphorylated to generate 5-amino-4-imidazolecarboxamide
ribotide (ZMP). ZMP mimics AMP and stimulates AMPK phosphorylation in the cell [161]. As
shown in Fig. 4.4, AICAR treatment alone decreased fat accumulation, while 10 M fipronil
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treatment alone increased fat accumulation. When cells were treated with AICAR and fipronil
together, the fat accumulation decreased, compared to fipronil treatment alone (Fig. 4.4).
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Figure 3.4. AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) abolished the increased
fat accumulation induced by fipronil. Cells were treated with fipronil (10 µM) or AICAR (40
µM) for 8 days. Numbers represent mean ± S.E. (n=3). Means with different letters were
significantly different at P<0.05.
3.3.5 Influence of AMPKα activation on protein expression of regulators controlling
adipogenesis
As expected (Fig. 3.5), AICAR treatment alone significantly decreased the expression of
C/EBPα, ACC, while expressions of pAMPKα and pACC were significantly increased compared
to controls. When cells were treated together with fipronil and AICAR, increased protein
expression of C/EBPα, ACC and decreased expression of pAMPKα and pACC induced by
fipronil were abolished by AICAR treatment. These results suggest that AMPKα activation could
abolish enhanced adipogenesis induced by fipronil.
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Figure 3.5. AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) abolished the increased
expression of C/EBPα, ACC and the decreased expression of PAMPKα, PACC induced by
fipronil. C/EBP-α, CAATT element binding protein-α; ACC, acetyl-CoA carboxylase (active
form); pAMPKα, phosphorylated AMPKα (active form); pACC, phosphorylated ACC. Cells
were treated with fipronil (10 µM) or AICAR (40 µM) for 8 days. Numbers represent mean ±
S.E. (n=3-4). Means with different letters were significantly different at P<0.05.
3.4 Discussion
Results from the current study suggest that fipronil exposure contributes to increased
adipogenesis in 3T3-L1 cell model. To our knowledge, this is the first report linking enhanced
adipogenesis to fipronil, particularly at 10 M. We further expand our understanding that
AMPKα pathway is involved in increased adipogenesis induced by fipronil.

34

AMPK is the downstream component of a protein kinase cascade that has a central role in
the regulation of energy balance and lipid metabolism [162]. Activation of AMPK has been
suggested to inhibit adipogenesis with reduced expression of PPAR, C/EBPα and late
adipogenic markers such as FAS and ACC [163]. Activation of AMPK has also been reported to
inhibit lipogenesis by phosphorylation of ACC, the key regulated step in fatty acid synthesis and
fatty acid oxidation. ACC catalyzes the synthesis of malonyl-CoA, a substrate of fatty acid
synthesis, and is inhibited by AMPK-mediated phosphorylation of ACC [164]. In the current
study, the concentration of AICAR used is 40 µM, which is lower than a previous report [163].
We tested the effects of different AICAR concentrations (40, 150 and 500 µM) on 3T3-L1
viability as well as adipogenesis. We found that all three doses can inhibit adipogenesis
effectively in our cell culture model. However, AICAR concentrations (150 and 500 µM)
decreased cell viability. Thus we chose AICAR (40 µM) in the following study. Our current
results suggest that fipronil may influence lipid metabolism via post-translational regulation of
AMPK. With the current results, it is not clear if fipronil directly or indirectly targets AMPK.
However, fipronil has previously been reported to increase intracellular Ca 2+ levels, by alteration
of the permeabilization of plasma membrane induced by fipronil [165]. Based on reports that
chronic elevation of intracellular calcium might impair the activation of AMPK, via
calcium/calmodulin kinase kinase-β (CaMKKβ) [166, 167], it is possible that fipronil may
influence intracellular calcium levels and lead to altered adipogenesis and lipid metabolism via
CaMKKβ-and AMPK- mediated mechanisms. However, fipronil’s effect on intracellular calcium
needs to be further confirmed in the future.
In the current study, no significant differences of leptin mRNA were found between
control and fipronil treatment groups in this model. Although we did not measure leptin secretion
in this study, it is known that expression of leptin is well correlated to leptin secretion in the 3T3L1 model. Previously, Lassiter and Brimijoin [150] reported that organophosphorus insecticide
treatment could impair leptin production. Two previous publications from our group consistently
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reported that imidacloprid and permethrin had no effect on leptin expression, which suggests
impaired leptin production by these insecticides [3, 6, 7]. Thus, the lack of effects of fipronil on
leptin expression might be due to impaired leptin signaling by fipronil treatment. This may also
contribute to altered lipid accumulation, as leptin plays an important role in regulating food intake
and glucose metabolism [168].
The toxicity symptoms of fipronil in mice include hyperactivity, irritability, convulsions,
leading to death [169, 170], with the oral LD50 of fipronil in rat being 97 mg/kg body weight
[169, 170]. Fipronil might potentially be a metabolic disorder, due to its ability to induce hepatic
phase I CYP enzymes, which have great potential to interact with other xenobiotics or
endogenous chemicals, which are substrates of the CYP1A, CYP2B and CYP3A subfamilies
[171]. The ADI (acceptable daily intake) of fipronil was determined to be 0.0002 mg/kg body
weight, based on the oral NOAEL (no observed adverse effect level) of 0.019 mg/kg body
weight/day in a 2-year study of toxicity and carcinogenicity in rats [169, 170]. The major
metabolite of fipronil detected in adipose tissue, liver, kidney, and muscle of rat was the fipronil
sulfone, while two main metabolites, fipronil sulfone and fipronil amide, were found in urine
[169, 170]. In a pharmacokinetics study of fipronil in rats using 14C-fipronil administered orally
at a single dose of 4 mg/kg body weight, the radioactivity in blood reached a maximum value 5.5
hours after treatment and decreased thereafter, with an elimination half-life of 183 hours. The
relative long half-life suggests the bioaccumulation of metabolic products from fipronil may
have occurred in adipose tissue [170]. In fact, the highest concentration of fipronil sulfone in
adipose tissue reported was 31 ppm, which is equivalent to ~70 μM [169, 170].
Currently, only limited information exists concerning the serum levels of fipronil in
humans. One occupational exposure study of workers at a fipronil production facility reported
fipronil sulfone serum level of 17.8 nM, although the levels of fipronil or its metabolites in
adipose tissue levels were not measured [172]. The plasma levels of total fipronil (including its
metabolites) in patients who were orally exposed to fipronil ranged from 0.12 to 9.15 μM [173].

36

Thus, levels of fipronil used in the present study were higher than potential exposure levels for
most populations.

Nevertheless, based on observation that fipronil and its metabolites

bioaccumulate in adipose tissue (~70 μM) [169, 170], the findings of the current study may have
significant implication for the role of fipronil on adipogenesis.
In comparison to the biological fate of fipronil above, it is also known to be degraded in
the environment through photolysis, oxidation, and reduction [146]. Fipronil is particularly
sensitive to photolysis with half-life of ~8 hr, resulting in desulfinyl fipronil as the primary
photolysis product [145]. This metabolite has a 10-fold higher affinity for mammalian GABA
receptors than parent fipronil and reduces selectivity substantially between insects and mammals
[145]. Thus, it is also important to determine the potential role of metabolites of fipronil from
both biological and environmental systems.
To summarize, our present finding reports the influence of fipronil on enhanced
adipocyte differentiation and increased fat accumulation in adipocytes and are significant in
providing a potential link between insecticide exposure, particularly fipronil, and impaired
adipocyte functions. Nonetheless, our current results are limited to an in vitro model using
relatively high doses of fipronil. In addition, the role of fipronil metabolites still needs to be
determined. Thus, further in vivo studies of fipronil, as well as epidemiological studies, are
necessary to further elucidate the significance of the current study.
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CHAPTER 4
IMIDACLOPRID PROMOTES HIGH FAT DIET-INDUCED ADIPOSITY AND
INSULIN RESISTANCE IN MALE C57BL/6J MICE

4.1 Introduction
Since its introduction to the market in 1991, imidacloprid
(N-{1-[(6-Chloro-3-pyridyl)methyl]-4,5-dihydroimidazol-2-yl}nitramide) is the most successful
neonicotinoid insecticide containing the 2-(N-nitroimidazolidin) pharmacophore and the (6chloropyrid-3-yl) methyl residue [174]. Imidacloprid has been widely used on various types of
grains, vegetables, fruits, and turf to control agricultural insect pests as well as on domesticated
animals to control ectoparasitic arthropods (e.g. K9 Advantix II and Advatage) [175-177]. In
2009, the market sales for imidacloprid in the US alone was estimated to be 1.1 billion USD
[175]. This extensive use of imidacloprid in agriculture, including seed dressing, in recent years
might further add to its soil [178, 179] and water [180] as well as detection in various kinds of
fresh and processed fruits and vegetables [39]. These suggest that the potential for human
exposure to imidacloprid, in the general public as well as agricultural workers, would be
relatively high. Imidacloprid use was restricted by the European Commission in 2013 along with
two other neonicotinoids due to its potential risk for the collapse of bee populations [43]. The
selective potency of imidacloprid to insects versus mammals has been well characterized and
attributed to the higher affinity at the insect nicotinic acetylcholine receptors (nAChRs) [40, 181184]. This selective action of imidacloprid and its systemic property make imidacloprid a
preferable choice of insecticide in various field situations [175]. In addition, imidacloprid is
relatively more water soluble when compared to other classes of insecticides (e.g.,
organochlorine, organophosphorus and pyrethroid insecticides) and penetrates human skin
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slowly. Imidacloprid is also known to be quite persistent with approximately a 39 days of
photolysis half-life at the soil surface (a range of 26.5-229 days) and an aerobic half-life of ~3
years [185]. Moreover, it is known that a plant metabolite, desnitro imidacloprid, has been
determined to be more toxic to mammals than the parent compound [186, 187].
Epidemiological studies suggest a link between exposure to persistent organic pollutants,
including insecticides, and the epidemic of obesity and diabetes[60, 91, 188-190]. Recently, one
animal study reported that exposure to contaminated salmon oil containing persistent organic
pollutants along with a high fat diet resulted in insulin resistance, represented by
hyperinsulinemia, glucose intolerance, and hypertriglyceridemia, as well as hepatic steatosis,
compared to control fed high fat diet alone in rats [191]. Another study reported that exposure to
dichlorodiphenyldichloroethylene (DDE) has a biphasic effect on fasting blood glucose in high
fat diet fed male mice [192]. Previously, a single study reported that 20 mg imidacloprid/kg body
weight/day through oral gavage decreased body weight accompanied with significant elevation of
serum glucose, glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT)
and blood urea nitrogen in rats, while 10 mg imidacloprid /kg body weight /day did not show
such toxic effect [193]. Another study concluded that imidacloprid (5 and 10 mg/kg bw/day) has
immunosuppressive effects, which might result from the direct cytotoxic effects of imidacloprid
against T-cells [177]. Moreover, there are recent reports that imidacloprid may have adverse
effects on development [194, 195]. Along with these reports, our previous published studies
reported that several pesticides, including imidacloprid, promotes adipogenesis in 3T3-L1
adipocytes and induces insulin resistance in C2C12 myotubes [6, 9, 196-198]. It is not known,
however, if imidacloprid exposure alone or in combination with other factors of obesity and
insulin resistance, such as high fat diet, will exacerbate obesity and insulin resistance symptoms.
Thus, the current study was conducted to determine if exposure to imidacloprid aggravated high
fat diet-induced metabolic disorders characterized by adiposity, dyslipidemia, hyperglycemia, and
insulin resistance in male C57BL/6J mice.
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4.2 Materials and Methods
4.2.1 Materials
Imidacloprid (>98%) was purchased from Chem Service Inc. (West Chester, PA, USA).
Three-week-old male C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor,
ME, USA). Semi-purified powdered diets (TD 94048, 4% fat w/w, low fat diet and TD 07518,
20% fat w/w, high fat diet) were based on Harlan Laboratories (Madison, WI, USA) diets. Food
ingredients were obtained from Bio-Serv (Flemington, NJ, USA). Glucose and total cholesterol
assay kits were purchased from Genzyme Diagnostics (Charlottetown, PE, Canada). Mouse leptin
assay kit was purchased from R & D Systems (Minneapolis, MN, USA). Non-esterified fatty acid
assay kit was from Wako Life Sciences, Inc. (Mountain view, CA, USA). Serum insulin level was
analyzed with Mouse insulin ELISA kit from ALPCO (Salem, NH, USA). The amounts of
triglyceride were quantified using Infinity™ Triglycerides Reagent from Thermo Scientific
(Waltham, MA, USA), and other chemicals were purchased from Fisher Scientific (Pittsburgh,
PA, USA). Radioimmunoprecipitation assay (RIPA) buffer supplemented with 1% protease
inhibitor was purchased from Boston Bioproducts Inc. (Ashland, MA, USA). Rabbit antibodies to
AMPKα, phosphorylated AMPKα (pAMPKα), acetyl-CoA carboxylase (ACC), phosphorylated
ACC (pACC) and horseradish peroxidase-conjugated goat anti-rabbit IgG were purchased from
Cell Signaling Technology (Beverly, MA, USA). Rabbit antibodies to Sirtuin 1 (SIRT1),
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), and β-actin
were purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). Ca2+/calmodulindependent protein kinase kinase β (CAMKKβ) rabbit antibody was purchased Abcam Inc.
(Cambridge, MA, USA). Human recombinant insulin (Novolin, 100 U/ml) was purchased from
Novo Nordisk Pharmaceuticals Industries Inc. (Seattle, WA, USA). Dextrose (50%) and
bacteriostatic 0.9% sodium chloride injection were obtained from Hospira, Inc. (Lake Forest, IL,
USA).
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4.2.2 Animals and diet
All animal work was conducted in compliance with the Institutional Animal Care and
Use Committee at the University of Massachusetts under protocol number 2013-0014. Mice were
housed in a temperature and humidity-controlled room with a 12-h light/dark cycle. The
compositions of diets are shown in Table 1. Diet and water were given to mice ad libitum
throughout the experiment and were provided fresh twice a week. Body weight and food intake
were monitored weekly. After 2-week adaptation, the mice were fed a control diet (4% fat w/w)
and subjected to baseline tests for insulin tolerance and glucose tolerance. All animals were then
divided to two dietary groups (low fat and high fat diet), each dietary treatment group contained
four imidacloprid treatment doses (0, 0.06, 0.6 and 6 mg/kg bw/day). The treatment lasted for 12
weeks. Doses of imidacloprid were determined based on previous publications; the highest
imidacloprid dose was based on no-observed-adverse-effect-level (NOAEL) of imidacloprid at
5.7 mg/kg bw/day and the lowest dose of imidacloprid was based on estimated average daily
intake of imidacloprid of 60 µg/kg body weight/day [199-201]. Imidacloprid content in low fat
diets were 0, 0.516, 5.16 and 51.6 mg imidacloprid/kg diet. Imidacloprid content in high fat diets
were 0, 0.744, 7.44 and 74.4 mg imidacloprid/kg diet. The average consumption of imidacloprid
at the end of the study was 0, 0.07, 0.7 and 7 mg/kg bw/day in low fat dietary groups and 0, 0.08,
0.8 and 7 mg/kg bw/day in high fat dietary groups. Imidacloprid intake between low fat diet and
high fat diet was not statistically different.
At the end of the study, mice were fasted for 4 h and sacrificed by CO 2 asphyxiation.
Blood was collected by cardiac puncture, and serum was separated by centrifugation at 2000 g for
20 min. The organs (kidney, heart, liver, spleen, pancreas and adipose tissues including
epididymal, mesenteric, retroperitoneal, and subcutaneous adipose tissues) were weighed
following sacrifice. One-eighth of the epididymal adipose tissue were kept in 10% buffered
formalin and used for adipocyte size determination. The other parts of the epididymal adipose
tissue and all other organs including gastrocnemius and quadriceps were snap frozen with liquid
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nitrogen and stored at -80 C until analysis.
Table 4.1. Composition of diet

Ingredient

Low fat diet
Amount (g/kg)

High fat diet
Amount (g/kg)

Casein

140

169.1

L-Cystine

1.8

2.2

Sucrose

100

100

Cornstarch

465.692

288.5

Maltodextrin

155

132

Cellulose

50

50

Soybean oil

40

200

Mineral mix, AIN-93M-MX (TD 94049)

35

42.8

Vitamin mix, AIN-93-VX (TD 94047)

10

12.4

Choline bitartrate

2.5

3

tert-Butylhydroquinone

0.008

0.04

Total

1000

1000

4.2.3 Serum parameters
The levels of total cholesterol, leptin, non-esterified fatty acids (NEFA), triglyceride (TG)
and insulin in serum were determined with commercial kits following the manufacturers’
instructions.

4.2.4 Insulin tolerance test
Insulin tolerance test (ITT) was performed during adaptation and treatment at week 5 and
week 9 as previously described [202]. All mice were fasted for 4 h. Blood glucose from the tail
vein was measured at 0, 15, 30, 60 and 120 min post intraperitoneal injection of insulin solution
(0.75 U/kg body weight), with a blood glucose meter, Advocate Redi-Code+ (Advocate Meters
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Inc., Dorado, Puerto Rico). The areas under the curve (AUC) were calculated with Sigma Plot
11.0 (Systat Software, Inc., San Jose, CA, USA).

4.2.5 Glucose tolerance test
Glucose tolerance tests (GTT) were performed during adaptation and treatment at week 6
and week 11 as described previously [202]. All mice were fasted for 6 h before the first
measurement of blood glucose from the tail vein and blood glucose was measured with a blood
glucose meter (0 min). Then, 20% glucose solution (2 g glucose/kg of body weight) was
administered intraperitoneally and blood glucose levels were further monitored at 15, 30, 60, and
120 min. Blood insulin level was also measured at 0, 30, 60 and 120 min with mouse insulin
ELISA kit from ALPCO (Salem, NH, USA). AUC were calculated with Sigma Plot. The
homeostasis model assessment- insulin resistance (HOMA-IR) score was calculated with HOMAIR calculator (University of Oxford) [203].

4.2.6 Adipocyte size measurement
Epididymal adipose tissue was fixed in 10% phosphate-buffered formalin and processed
for paraffin sectioning [204]. Tissue sections (4 µm) were cut and stained with hematoxylin and
eosin (HE) staining. Pictures were taken with Olympus CK2 inverted microscope (Olympus,
Tokyo, Japan) (100 x magnification) and microscope eyepiece camera (AmScope, Irvine, CA).
Adipocyte size was measured as previously described with Image J software with minor
modification [205]. Mean area of 50 cells from each sample were measured with Image J
software. Briefly, the pictures of calibration slide (AmScope, Irvine, CA) were taken under the
same settings as the tissue sections and were used to set the scale in image J, then the area of the
adipocytes were measured with Image J.
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4.2.7 mRNA expression analysis
Mouse epididymal adipose tissue, liver, and gastrocnemius muscle were homogenized in
Trizol reagent to extract total RNA under RNase free conditions. Total RNA was reversetranscribed with high-capacity reverse transcription kit (Applied Biosystems, Carlsbad, CA).
mRNA expression levels of fatty acid translocase (FAT/CD36), sterol regulatory element-binding
protein 1c (SREBP1c), tumor necrosis factor α (TNF-α), phosphoenolpyruvate carboxykinase
(PEPCK), peroxisome proliferator-activated receptor alpha (PPARα), glucose transporter type 4
(GLUT4), pyruvate dehydrogenase kinase 4 (PDK4), carnitine palmitoyltransferase 1B (CPT1b),
and 18S ribosomal RNA (18S rRNA) were analyzed. Real-time polymerase chain reaction (PCR)
was completed using a StepOne Plus real time PCR instrument (Applied Biosystems, Carlsbad,
CA, USA) and Taqman probe-based gene expression analysis (Applied Biosystems, Carlsbad,
CA, USA). Respective integrated sequences used were NM_001159555.1 (CD36), NM_011480.3
(SREBP1c), NM_001278601.1 (TNFα), NM_028994.2 (PEPCK), NM_001113418.1 (PPARα),
NM_009204.2 (GLUT4), NM_013743.2 (PDK4), NM_009948.2 (CPT1b), and NR_003278.3
(18S rRNA).

4.2.8 Immunoblotting
Mouse tissues were prepared for immunoblotting as previously described [198]. Protein
quantities were determined using the assay kit (Bio-Rad Co., Hercules, CA). β-actin was used as
an internal control. The secondary antibody was goat anti-rabbit IgG conjugated with horseradish
peroxidase. Detections were performed on an image Station 4000MM (Carestream Health, New
Haven, CT) with ClarityTM Western ECL Substrate Kit (Bio-Rad Co., Hercules, CA, USA).
Images were quantified with Image J software [155].
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4.2.9 Statistical analyses
Data were analyzed by PROC MIXED of the SAS software (Version 9.3, SAS Institute
Inc., Cary, NC, USA). For the result on body weight (Figure 1A), two-way repeated measure
Analysis of Variance (ANOVA) and the slice option in the Least Square (LS) means statement
were used to determine the differences at each time point. For all the other results, two-way
ANOVA along with LS means statement was used. The Tukey-Kramer’s method was applied for
the multiple comparisons among the groups. P-values less than 0.05 are reported as statistically
significant. If there were significant interactions between diet and imidacloprid, letters were used
in the figures to present the differences between each group. When there were no interactions
between diet and imidacloprid, brackets were used in the figures to represent overall differences
between imidacloprid treatments and control groups.

4.3 Results
4.3.1 Imidacloprid promoted weight gain in high fat diet fed mice
To understand the effect of imidacloprid on dietary fat induced changes, we chose
C57BL/6J male mice fed with either low fat (4%) or high fat (20%) diet. High fat diets (~40-70%
of kcal) are known to induce obesity in this strain[206]. There were overall effects of diet or
imidacloprid on body weight (Fig. 4.1A). Significant 3-way interaction (imidacloprid x diet x
time) was also observed. In high fat diet fed mice, all imidacloprid groups showed significant
increase in body weight compared to the control group from week-7 onward and maintain the
trend throughout the experiment (p<0.001 for all weeks from 7 to 12) (Fig. 4.1A). No differences
of body weight were found in the low fat diet fed mice among all groups throughout the
experiment (Fig. 4.1A). Overall, both dietary fat and imidacloprid significantly affected body
weight gain and there was a significant interaction between dietary fat and imidacloprid (Fig.
4.1B). In high fat diet fed mice, imidacloprid treatment groups (0.06, 0.6 and 6 mg/kg bw/day)
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had significantly greater weight gain compared to the high fat control group (p=0.0057, 0.0149
and 0.0038, respectively) (Fig. 4.1B).
Food intake as determined by calorie consumption is shown in Fig. 4.1C.

Both

imidacloprid and dietary fat significantly affected the calorie intake alone but without any
interaction between them (Fig. 4.1C). Mice fed with high fat diet had more calorie intake
compared to mice fed with low fat diet (p=0.0080). There were no significant differences of
calorie intake between control and three imidacloprid treatment groups. However, there was
significant difference of calorie intake between 0.06 and 6 mg/kg bw/day imidacloprid treatment
groups (p=0.0223) (Fig. 4.1C).
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Figure 4.1. Effects of imidacloprid on body weight, body weight gain and food intake. Mice were
fed with low fat diet or high fat diet supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day)
imidacloprid for 12 weeks. (A) Body weight was monitored weekly, (B) Body weight gain for 12
weeks. (C) Total food intake. Numbers are mean ± S.E. (n=5-8 for A & B, n=3-4 for C). Means
with different letters were significantly different at P<0.05.
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4.3.2 Influence of imidacloprid on tissue and organ weights
Organ weights (liver, pancreas, heart, kidneys, and spleen) as well as adipose tissue
weights (epididymal, subcutaneous, mesenteric, retroperitoneal, and total adipose tissue)
measured as % of body weights are shown in Table 4.2. There was a significant diet effect, but
there were no imidacloprid and diet x imidacloprid interaction effects on liver, heart and spleen
weights. Both imidacloprid and diet significantly affected the kidney weight with a significant
interaction. In high fat diet fed mice, imidacloprid treatment groups (0.06 and 6 mg/kg bw/day)
had reduced kidney weight compared to control group (p=0.0297 and 0.0006, respectively).
There were overall effects of diet and imidacloprid on all adipose tissue weights with interaction,
except for mesenteric adipose tissue, where only a diet effect was observed. In high fat diet fed
mice, animals treated with imidacloprid (0.6 and 6 mg/kg bw/day) had significantly greater
epididymal (p=0.0337 and 0.0002, respectively) and retroperitoneal (p=0.0078 and 0.0008,
respectively) adipose tissue weights compared to control group.
Histological analysis revealed that there were significant effects of diet and imidacloprid
with diet x imidacloprid interaction on epididymal adipocyte size (Fig. 4.2). Imidacloprid (0.06,
0.6 and 6 mg/kg bw/day) treatment significantly increased adipocyte size in high fat diet fed mice
(p=0.0081, 0.0002 and 0.0001, respectively), but not in low fat diet fed mice (Fig. 4.2A & 4.2B).

4.3.3 Influence of imidacloprid on serum markers
The serum levels of glucose, cholesterol, leptin, NEFA, TG and insulin are shown in
Table 4.3. There were overall treatment effects from both diet and imidacloprid (without
interaction) on blood glucose and insulin levels. Mice fed with imidacloprid (0.06 and 6 mg/kg
bw/day) had significantly higher levels of blood glucose compared to control groups (p=0.0096
and 0.0144, respectively). Mice fed with imidacloprid (6 mg/kg bw/day) also had significantly
higher blood insulin levels compared to control groups (p=0.0325). There were overall treatment
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effects from both diet and imidacloprid with their interaction on leptin level. Compared to the
high fat control group, animals fed the high fat diet with (0.06, 0.6 and 6 mg/kg bw/day)
imidacloprid had higher blood leptin levels (p<0.0001, 0.0011 and <0.0001, respectively). There
were overall treatment effects from imidacloprid, but not diet and their interaction, on serum TG
levels. Mice fed with imidacloprid (6 mg/kg bw/day) had significantly higher serum TG level
compared to control groups (p=0.0099). There were significant effects of diet, but not to
imidacloprid nor to their interaction, on cholesterol levels. There were no significant effects of
both diet and imidacloprid on serum NEFA levels.

4.3.4 Effects of imidacloprid on glucose homeostasis
To determine the effect of imidacloprid and diet on glucose homeostasis, we measured
serum glucose levels during ITT and GTT and measured serum insulin level during GTT, which
were presented in Fig. 4.3. Before treatment, there were no differences between any of the groups
for ITT, GTT and insulin level (Fig. 4.3A, 4.3D & 4.3G).
As shown in Fig. 4.3B, there were significant diet and imidacloprid effects without
interaction on insulin tolerance after 5-week treatment. In particular, mice that received the
highest dose of imidacloprid (6 mg/kg bw/day) had significantly higher AUC compared to control
groups (p=0.0018) in week 5 (Fig. 4.3B). After 9-week treatment, there were significant effects of
diet and imidacloprid with interaction (Fig. 4.3C). High fat diet imidacloprid treated mice at 6
mg/kg bw/day had significantly elevated AUC compared to the high fat control (p=0.0006) (Fig.
4.3C).
We further performed GTT at 6 and 11-week. As shown in Fig. 5.3E, only diet was found
to have significant effect on impaired glucose tolerance in week 6. In week 11, both diet and
imidacloprid effects were observed without interaction (Fig. 4.3F). At the highest dose of
imidacloprid (6 mg/kg bw/day), treated mice showed more severe glucose intolerance compared
to control groups (p=0.0331) (Fig. 4.3F).

49

The serum samples collected from the GTT tests were further utilized for insulin level
measurements. There were significant diet and imidacloprid effects with interaction on serum
insulin level both at week 6 and 11 (Fig. 4.3H & 4.3I). High fat diet with imidacloprid treated
animals at 0.6 and 6 mg/kg bw/day had significantly higher AUC of insulin levels compared to
high fat controls (p<.0001 for both 0.6 and 6 mg/kg bw/day at week 6, p=0.0007 and 0.0211 at
week 11, respectively) (Fig. 4.3H & 4.3I). Similarly, there were significant diet and imidacloprid
effects on HOMA-IR scores with significant interaction in week 6, 11 and 12 (Fig. 4.4). High fat
diet with imidacloprid (0.6 and 6 mg/kg bw/day) treated mice had higher HOMA-IR scores
compared with the high fat control (Fig. 4.4).
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Table 4.2. Organ Weights (% of body weight)

Low fat

High fat
P-value

Imidacloprid doses

Imidacloprid doses

Control

0.06 mg/kg

0.6 mg/kg

6 mg/kg

Control

0.06 mg/kg

0.6 mg/kg

6 mg/kg

Dietary
fat

Imidacloprid

Interaction

Liver

3.90 ± 0.12

3.86 ± 0.15

3.78 ± 0.07

3.92 ± 0.16

3.51 ± 0.18

3.57 ± 0.08

3.34 ± 0.21

3.58 ± 0.17

0.002

n.s.

n.s.

Heart

0.44 ± 00.02

0.50 ± 0.05

0.48 ± 0.02

0.48 ± 0.02

0.47 ±0.03

0.41 ± 0.03

0.41 ± 0.03

0.38 ± 0.03

0.011

n.s.

n.s.

Spleen

0.26 ± 0.03

0.20 ± 0.01

0.23 ± 0.02

0.19 ± 0.02

0.30 ± 0.02

0.27 ± 0.02

0.30 ± 0.01

0.35 ± 0.05

0.0002

n.s.

n.s.

Kidney

1.06 ± 0.05ab

1.09 ± 0.05ab

1.15 ± 0.04a

1.10 ± 0.04ab

1.12 ± 0.07a

0.88 ± 0.04bc

0.96 ± 0.03abc

0.80 ± 0.05c

<0.0001

0.027

0.003

Pancreas

0.43 ± 0.04

0.45 ± 0.02

0.48 ± 0.04

0.47 ± 0.03

0.54 ± 0.05

0.38 ± 0.02

0.42 ± 0.02

0.39 ± 0.04

n.s.

n.s.

0.037

Epididymal

2.19 ± 0.20d

2.29 ± 0.42cd

1.64 ± 0.17d

2.00 ± 0.25d

3.57 ± 0.42bc

5.0 ± 0.31ab

5.03 ± 0.27a

5.82 ± 0.40a

<0.0001

0.011

0.001

Subcutaneous

1.36 ± 0.24cd

1.43 ± 0.37cd

0.94 ± 0.14d

1.43 ± 0.30cd

2.65 ± 0.45bc

3.79 ± 0.37ab

3.59 ± 0.28a

4.91 ± 0.56a

<0.0001

0.014

0.026

Retroperitoneal

0.59 ± 0.08c

0.57 ± 0.13c

0.39 ± 0.08c

0.51 ± 0.09c

1.09 ± 0.12b

1.50 ± 0.09ab

1.64 ± 0.09a

1.75 ± 0.14a

<0.0001

0.038

0.001

Mesenteric

1.33 ± 0.10

1.61 ± 0.20

1.23 ± 0.15

1.23 ± 0.11

2.02 ± 0.23

2.60 ± 0.19

2.64 ± 0.17

2.80 ± 0.26

<0.0001

n.s.

n.s.

Total

5.47 ± 0.58bc

5.90 ± 1.10bc

4.20 ± 0.52c

5.17 ± 0.74bc

9.34 ± 1.12b

12.9 ± 0.88a

12.9 ± 0.68a

15.3 ± 1.29a

<0.0001

0.001

<0.001

Adipose tissue

Mice were treated with three doses of imidacloprid (0.06, 0.6 and 6 mg/kg bw/day). Values represent means ± SE (n=5-8).
Means with different superscripts within the same row are significantly different at P<0.05. Abbreviations: n.s., not significant.
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Table 4.3. Serum Parameters

Low fat

High fat
P-value

Imidacloprid doses

Imidacloprid doses

Control

0.06 mg/kg

0.6 mg/kg

6 mg/kg

Control

0.06 mg/kg

0.6 mg/kg

6 mg/kg

Dietary
fat

Imidacloprid

Interaction

Glucose
mg/dL

162.8 ± 7.9

183.1 ± 24.1

169.7 ± 4.6

169.3 ± 17.7

178.2 ± 17.9

234.7 ± 19.1

193.7 ± 18.7

229.9 ± 15.4

0.0312

0.0034

n.s.

Insulin
ng/mL

0.77 ± 0.11

0.97 ± 0.25

0.81 ± 0.07

0.97 ± 0.21

2.05 ± 0.34

3.10 ± 0.33

2.51 ± 0.37

3.36 ± 0.58

<0.0001

0.0312

n.s.

Leptin
ng/mL

4.9 ± 1.0b

4.2 ± 1.4b

3.4 ± 0.7b

4.4 ± 1.2b

14.4 ± 3.7b

59.6 ± 3.2a

47.9 ± 6.1a

66.4 ± 11.5a

<0.0001

<0.0001

<0.0001

TG
mg/dL

77.2 ± 6.3

94.2 ± 6.1

76.3 ± 12.2

91.2 ± 8.1

63.6 ± 5.1

82.4 ± 6.0

85.0 ± 2.3

94.5 ± 6.8

n.s.

0.0104

n.s.

Cholesterol
mg/dL

161.5 ± 8.7

163.7 ± 18.9

117.6 ± 11.3

150.5 ± 9.5

171 ± 15

213.4 ± 21

182.6 ± 16

219.9 ± 21.9

0.0003

n.s.

n.s.

NEFA
mEq/L

1.3 ± 0.1

1.4 ± 0.1

1.1 ± 0.1

1.2 ± 0.1

1.0 ± 0.2

1.1 ± 0.1

1.2 ± 0.1

1.2 ± 0.1

n.s.

n.s.

n.s.

Mice were treated with three doses of imidacloprid (0.06, 0.6 and 6 mg/kg bw/day). Values represent means ± SE (n=5-8). Means with different
superscripts within the same row are significantly different at P<0.05. Abbreviations: n.s., not significant; TG, triglyceride; NEFA, non-esterified
fatty acid.
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Figure 4.2. Effects of imidacloprid on adipocyte size. Mice were fed with low fat diet or high fat
diet supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day) imidacloprid for 12 weeks. (A)
Representative pictures of epididymal adipose tissues after H&E staining (100 x magnification).
(B) Adipocyte size. The mean area of 50 cells from each sample were measured with image J.
Data were expressed as the mean ± SE (n=3). Means with different letters were significantly
different at P<0.05.
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Figure 4.3. Effects of imidacloprid on insulin tolerance test (ITT) (A, B, C), glucose tolerance test
(GTT) (D, E, F) and insulin level determination with serum from GTT (G, H, I) as the area under
the curve (AUC). Mice were fed with low fat diet or high fat diet supplemented with (0, 0.06, 0.6
and 6 mg/kg bw/day) imidacloprid for 12 weeks. ITT was measured during adaptation period,
week 5 and 9. GTT was measured during adaptation period, week 6 and 11. Blood was collected
from the tail vein, and glucose levels were determined at 0 min, then the insulin (ITT) or glucose
solution (GTT) was administered by intraperitoneal injection and glucose level were further
measured at 15, 30, 60 and 120 min. During GTT, the blood was collected from the tail vein at 0,
30, 60 and 120 min for determination of insulin level. Numbers represent means ± SE (n=5-8).
Means with different letters were significantly different at P<0.05.
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Figure 4.4. Effects of imidacloprid on HOMA-IR score. Mice were fed with low fat diet or high
fat diet supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day) imidacloprid for 12 weeks. HOMAIR score was calculated during adaptation period, week 6, 11 and 12 with HOMA-IR
calculator[203]. Numbers represent mean ± S.E. (n=5-8). Means with different letters were
significantly different at P<0.05.
4.3.5 Effects on mRNA levels of genes regulating lipid metabolism and AMPKα pathway in
epididymal adipose tissue
Since imidacloprid and high fat diet significantly affected the lipid and glucose
metabolism in mice, we first investigated their effects on mRNA expression levels of genes
regulating lipid metabolism in white adipose tissue. CD36, one of the fatty acid transporter
proteins in adipocytes, facilitates the cellular entry of lipoprotein derived fatty acids, thus
promoting the storage of triglycerides in adipose tissue [207]. There were significant diet and
imidacloprid effects without interaction on CD36 mRNA expression (Fig. 4.5A). Compared to
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control groups, mice fed with imidacloprid (6 mg/kg bw/day) had significantly higher expression
of CD36 (p=0.011) (Fig. 4.5A).
SREBP1c is highly expressed in adipose tissue and is a well-known master regulator of
the lipogenic pathway [208, 209]. There was significant imidacloprid, without diet effects or
interaction, on SREBP1c mRNA expression in the current study (Fig. 4.5B). Mice fed with 6
mg/kg bw/day imidacloprid had a significant increase in SREBP1 expression compared to
controls (p=0.0035) (Fig. 4.5B).
TNF-α, a pro-inflammatory cytokine, is highly expressed in the adipose tissue of obese
mice [210]. TNF-α is regarded as an important link between obesity and insulin resistance [211].
There were significant effects of diet and imidacloprid as well as their interaction on TNFα
expression (Fig. 4.5C). Mice with high fat diet and imidacloprid at 6 mg/kg bw/day had increased
TNFα mRNA expression level compared to high fat control (p=0.0029) (Fig. 4.5C).
AMPK is known as a master regulator of energy metabolism and activation of AMPK
leads to the stimulation of fatty acid oxidation and inhibition of lipogenesis [212]. Previously we
reported that imidacloprid may potentiate adipogenesis via AMPK mediated mechanism in 3T3L1 adipocytes [196]. To determine if oral administration of imidacloprid exerts its effect via a
similar mechanism, we have detected AMPK and its downstream target (acetyl Co-A
carboxylase, ACC) as well as one of its upstream regulator CaMKKβ [213, 214]. from
epididymal adipose tissue (Fig. 4.5D-4.5G). There were significant imidacloprid and imidacloprid
x diet interaction effects without diet effect on the expression of CaMKKβ (Fig. 4.5E). High fat
diet with imidacloprid (6 mg/kg bw/day) had significantly reduced expression of CaMKKβ
compared to controls (p= 0.0002) (Fig. 4.5E). There were significant diet and imidacloprid effects
with interaction on the ratio of expressions of pAMPKα/AMPKα (Fig. 4.5F). High fat diet and
imidacloprid (6 mg/kg bw/day) fed mice had a significant decrease in the ratio of
pAMPKα/AMPKα compared to high fat control (p= 0.0028) (Fig. 4.5F). There was only
imidacloprid effect, without diet effect, on the ratio of phosphorylated ACC/ACC (pACC/ACC)
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(Fig. 4.5G). Mice treated with imidacloprid at 0.06 and 6 mg/kg bw/day had significantly lower
pACC/ACC ratios compared to controls (p=0.015 and 0.0403, respectively) (Fig. 4.5G). These
results suggest that oral administration of imidacloprid might promote adipogenesis via
CaMKKβ-AMPKα dependent pathway in white adipose tissue of mice.
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Figure 4.5. Effects of imidacloprid on molecular target genes involved in lipid metabolism and
inflammation in white adipose tissue. Mice were fed with low fat diet or high fat diet
supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day) imidacloprid for 12 weeks. A. FAT/CD36,
fatty acid translocase; B. SREBP1c, sterol regulatory element-binding protein-1c; C. TNFα,
tumor necrosis factor-α; D. Representative pictures; E. CaMKKβ, Ca2+/calmodulin-dependent
protein kinase kinase β; F. pAMPKα/AMPKα, phosphorylated AMP-activated protein kinaseα/AMP-activated protein kinase-α; G. pACC/ACC, phosphorylated acetyl-CoA
carboxylase/acetyl-CoA carboxylase. Numbers represent mean ± S.E. (n=4-6). Means with
different letters were significantly different at P<0.05.
4.3.6 Effects on expression of genes regulating lipid and glucose metabolism as well as
AMPKα pathway in liver
Liver is an important organ in regulating glucose and fatty acid metabolisms, thus, we
further investigated the effects of imidacloprid and high fat diet on two genes; PEPCK and
PPARα, which is the rate-limiting enzyme for gluconeogenesis [215] and a key regulator of fatty
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acid oxidation in liver, respectively [216]. There were significant diet and imidacloprid effects
with their interaction on the expression of PEPCK (Fig. 4.6A). In mice fed with high fat diet,
imidacloprid (0.06 and 6 mg/kg bw/day) treatment groups showed significantly higher mRNA
expression of PEPCK, compared to control (p=0.0166 and 0.0336) (Fig. 4.6A). There were
significant diet and imidacloprid effects without interaction on PPARα mRNA expression (Fig.
4.6B). Mice fed imidacloprid at 0.6 and 6 mg/kg bw/day had significantly reduced mRNA
expression of PPARα compared to controls (p=0.0159 and 0.023, respectively) (Fig. 4.6B).
We further investigated the effect of imidacloprid on protein markers important for lipid
and glucose homeostasis in the liver. PGC-1α is highly expressed in the liver and is known as a
master regulator of fatty acid oxidation [217, 218]. Two metabolic sensors, AMPK and SIRT1,
have been reported to directly increase PGC-1α activity [219]. CaMKKβ is known to be the
upstream regulator of AMPK [213]. There were significant effects of imidacloprid and
imidacloprid x diet interaction without significant effect of diet on CaMKKβ expression (Fig.
4.6D). High fat diet with 6 mg/kg bw/day imidacloprid fed mice had a decrease in expression of
CaMKKβ compared to high fat control (p=0.0049) (Fig. 4.6D). Significant effects of diet and
imidacloprid with their interaction were observed for pAMPKα/AMPKα and pACC/ACC ratio
(Fig. 4.6E & 4.6F). High fat imidacloprid (6 mg/kg bw/day) fed mice exhibited a decreased ratio
of pAMPKα/AMPKα and pACC/ACC compared to high fat control (p<0.0001 and p=0.0475,
respectively) (Fig. 4.6E & 4.6F). There were effects of both diet and imidacloprid on SIRT1 and
PGC-1α expression without interaction (Fig. 4.6G & 4.6H). Mice treated with imidacloprid (0.6
and 6 mg/kg bw/day) had a significant decrease in expression of SIRT1(p=0.0026 and 0.0121)
and PGC-1α compared to controls (p=0.0356 and 0.011, respectively) (Fig. 4.6G & 4.6H). These
results suggest that imidacloprid might contribute to decreased fatty acid oxidation in the liver.

4.3.7 Effects on expression of genes regulating lipid and glucose metabolism in muscle
Muscle is responsible for 70-90% of glucose disposal in our body [220] and insulin
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resistance in skeletal muscle is the primary defect in type 2 diabetes [221]. In muscle, GLUT4 is
the main glucose transporter responsible for glucose uptake in response to insulin stimulation
[222]. It has been reported that mice lacking or overexpressing GLUT4 have a decrease or
increase in whole-body insulin sensitivity, respectively [223]. In the current study, there were
significant effects of diet and imidacloprid without interaction on muscle GLUT4 mRNA
expression (Fig. 4.7A). Mice fed with imidacloprid at 0.06 and 6 mg/kg bw/day had significantly
lower mRNA expression of GLUT4 compared to controls (p=0.0003 and 0.0012, respectively)
(Fig. 4.7A).
PDK4, a kinase enzyme highly expressed in skeletal muscle, inactivates the enzyme
pyruvate dehydrogenase [224]. As a result, the pyruvate formed from glycolysis cannot be
oxidized, which leads to hyperglycemia due to the decrease in blood glucose oxidation [225]. A
previous study also reported that PDK4 is overexpressed in skeletal muscle of people with type 2
diabetes, resulting in impaired glucose disposal [226]. In the current mice study, there were
effects of diet and imidacloprid on PDK4 mRNA expression without interaction (Fig. 4.7B). Mice
fed with imidacloprid at 6 mg/kg bw/day had higher expression level of PDK4 compared to
controls (p=0.0015) (Fig. 4.7B).
CPT1 is a mitochondrial transmembrane enzyme, recognized as rate limiting for
mitochondrial fatty acid β-oxidation [227]. In the current study, there was a significant diet effect
on CPT1 mRNA expression without imidacloprid effect and interaction. Taken together, these
results suggested that imidacloprid and high fat diet might affect the expression of genes
important for lipid and glucose metabolism and contribute to adiposity and insulin resistance in
the current study.
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Figure 4.6. Effects of imidacloprid on molecular target genes regulating lipid and glucose
metabolism as well as the AMPKα pathway in liver. Mice were fed with low fat diet or high fat
diet supplemented with (0, 0.06, 0.6 and 6 mg/kg bw/day) imidacloprid for 12 weeks. A. PEPCK,
phosphoenolpyruvate carboxykinase; B. PPARα, peroxisome proliferator-activated receptor-α; C.
Representative pictures. D. CaMKKβ, Ca2+/calmodulin -dependent protein kinase kinase β; E.
pAMPKα/AMPKα, phosphorylated AMP-activated protein kinase-α /AMP-activated protein
kinase-α; F. pACC/ACC, phosphorylated acetyl-CoA carboxylase/acetyl-CoA carboxylase; G.
SIRT1, sirtuin 1; H. PGC-1α, peroxisome proliferator-activated receptor-γ coactivator-1α.
Numbers represent mean ± S.E. (n=4-6). Means with different letters were significantly different
at P<0.05.
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Figure 4.7. Effects of imidacloprid on markers regulating lipid and glucose metabolism in muscle.
Mice were fed with low fat diet or high fat diet supplemented with (0, 0.06, 0.6 and 6 mg/kg
bw/day) imidacloprid for 12 weeks. A. GLUT4, glucose transporter type 4; B. PDK4, pyruvate
dehydrogenase kinase 4; CPT1, carnitine palmitoyltransferase 1. Numbers represent mean ± S.E.
(n=4-6). Means with different letters were significantly different at P<0.05.
4.4 Discussion
In this study, we demonstrated that dietary exposure to relatively low doses of
imidacloprid (at or lower than NOAEL) exacerbated high fat diet induced weight gain and insulin
resistance in C57BL/6J male mice during 12-week treatment. As such, it is the first mouse study
demonstrating the role of imidacloprid on development of high fat diet induced obesity and type 2
diabetes. The current results also suggest that imidacloprid may elicit its effects by posttranslational regulation of AMPK via CaMKKβ and/or SIRT1 in adipocytes and the liver. This
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finding is consistent with our previous reports that imidacloprid inhibits the phosphorylation of
AMPKα in 3T3-L1 adipocytes [196].
Several studies have reported an interaction between organophosphorous insecticides
(diazinon and parathion) and high fat diet, including their contribution to increased weight gain
and insulin resistance [228-232]. Ruzzin et al. [191] reported that persistent organic pollutants
(POP) in crude fish oil exacerbated high fat diet induced increased visceral adipose tissue and
insulin resistance compared to refined salmon oil (without POP) in male Sprague-Dawley rats. In
the Ruzzin study, POP with high fat diet was reported to induce increased liver SREBP1c
expression. Similarly, imidacloprid exposure increased the expression of SREBP1c in adipose
tissue in the current study. In addition, our current results showed that imidacloprid with high fat
diet increased TNFα (a pro-inflammatory cytokine) in adipose tissue of high fat diet fed mice,
which may have significance in insulin resistance.
A previous mice study reported that exposure to DDE initially facilitated high fat diet
induced hyperglycemia at weeks 4 and 8, which returned to normal at 12-13 weeks [192].
However, Ruzzin et al. [191] reported that POP with high fat diet increased HOMA-IR score and
reduced insulin-stimulated glucose uptake in skeletal muscle and adipose tissue. This report is
consistent with the current results that imidacloprid with high fat diet increased the blood glucose
and insulin levels along with impaired insulin resistance. Moreover, we observed that animals fed
imidacloprid with high fat diet potentiated gluconeogenesis in the liver by targeting PEPCK and
reduced glucose disposal from the skeletal muscle by decreasing GLUT4 expression and glucose
oxidation, both of which may have contributed to overall impairment of glucose homeostasis. It is
important to point out, however, that our results are limited since we did not measure insulin
stimulated GLUT4 translocation in skeletal muscle. Nevertheless, it was previously reported that
imidacloprid exposure might induce insulin resistance by reducing insulin stimulated glucose
uptake, and phosphorylation of protein kinase B (AKT) in adipocytes, hepatocytes and myotubes
[9]. Thus, it is likely that imidacloprid exacerbated high fat diet induced insulin resistance by
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targeting insulin signaling pathway. Alternatively, imidacloprid might cause oxidative stress and
inflammation as previously suggested [233-237]. Inflammation, including the significance of proinflammatory cytokine TNFα, and oxidative stress were reported to be correlated with
development of obesity and insulin resistance [8, 211, 238, 239]. Inflammation and oxidative
stress are known to activate JNK (c-Jun N-terminal kinase) [240, 241], which is linked to insulin
resistance [242]. Thus, further studies of imidacloprid’s role in oxidative stress and inflammation,
including the role of TNFα, and their contributions to obesity and insulin resistance, are needed to
understand how imidacloprid elicits altered metabolism.
Mice fed with high fat diet showed physiological and metabolic changes compared to low
fat diet fed mice as expected [243-246]; including increased body weight, calorie intake, serum
insulin level, HOMA-IR score, expression of epididymal adipose tissue CD36, TNFα, adipocyte
size and impaired insulin tolerance as well as glucose tolerance. However, several studies
reported inconsistent results of lipogenesis in mice consuming a high fat diet; increased [247], no
change [248] or decreased lipogenesis after high fat diet feeding [249, 250]. Our current results
show no significant different expression levels of SREBP1, a key lipogenic gene, in adipose
tissue between high fat diet and low fat diet fed mice.
Imidacloprid is the most widely used neonicotinoid insecticide [175] and compared to
highly lipophilic organochlorine and organophosphorus insecticides, imidacloprid is relatively
water-soluble [185]. Imidacloprid is considered to be moderately toxic, with oral LD50 in rats is
420 mg/kg body weight, and the typical symptoms of poisoning include fatigue, cramps, and
muscle weakness [251]. However, the dose we used in the current study was based on NOAEL of
5.7 mg imidacloprid/kg body weight/day or lower, thus we did not expect any of those acute toxic
symptoms in these animals [252]. A previous mice study showed that oral gavage of > 5 mg/kg
bw/day imidacloprid for 28 days resulted in immunosuppressive effects, however no changes in
body weight were observed for all doses of imidacloprid treatment in that study [177]. Another
study reported that oral administration of 20 mg/kg bw/day imidacloprid decreased the body
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weight in rats, however, this was not observed in 10 mg/kg bw/day imidacloprid treated rats
[193]. Thus, the significance of the current study is the interaction between high fat diet and
imidacloprid, which would have significance for understanding potential health implications of
imidacloprid.
It is known that imidacloprid is quickly absorbed from the gastrointestinal tract and
distributed in almost all organs and tissues [199]. The oral absorption of imidacloprid was
estimated as 92-99% [199]. Although imidacloprid intake between low fat diet and high fat diet in
the current study were not statistically different, we cannot exclude the possibility that high fat
and low fat diet might have different effects on the bioavailability of imidacloprid, thus leading to
the differences observed in the current study. Once absorbed, imidacloprid is degraded into a
variety of metabolites: 6-chloronicotinic acid, imidazolidine 4- and 5- hydroxy compounds,
olefinic imidacloprid, desnitro-imidacloprid and the nitrosoimine compound [199]. These
metabolites are known to be excreted mainly in the urine as glutathione and glycine conjugates of
mercaptonicotinic acid and hippuric acid [199]. Imidacloprid also photo-degrades rapidly in
water with a half-life of less than 3 hours. However, imidacloprid has been found to be persistent
in the environment with a photolysis half-life of 39 days at the soil surface (a range of 26.5-229
days) when absorbed by the soil [185].
Despite intensive investigations and establishment of preventive and therapeutic
strategies for obesity and type 2 diabetes, these diseases have increased significantly in the past
few decades [253, 254]. Sedentary lifestyle and excessive caloric intake can only partially explain
the dramatic increase of metabolic diseases worldwide. Recently, air pollution and environmental
contaminants such as bisphenol A, as well as other POP, are suggested to contribute to the
development of obesity and insulin resistance [191, 255-257]. Along with the current results,
these reports provide compelling evidence that environmental contaminants may contribute to the
epidemic of obesity, insulin resistance and eventually type 2 diabetes.
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To conclude, our present finding is the first report that imidacloprid exposure aggravates
high fat diet induced obesity and insulin resistance in C57BL/6J male mice. The current results
are significant in substantiating a potential link between insecticide exposure, particularly
imidacloprid, to dietary fat and adiposity as well as insulin resistance. However, the underlying
mechanisms by which imidacloprid promotes high fat diet induced obesity and insulin resistance
still need to be further explored in the future.
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CHAPTER 5

IMIDACLOPRID PROMOTES HIGH FAT DIET-INDUCED ADIPOSITY IN FEMALE
C57BL/6J MICE AND ENHANCE ADIPOGENESIS IN 3T3-L1 ADIPOCYTES VIA
AMPKα-MEDIATED PATHWAY

5.1 Introduction

Among the major classes of insecticides, neonicotinoids are the largest single
insecticide class on the market currently, representing approximately 27% of global
insecticide use in 2013 [258]. Since its commercial introduction in 1991, imidacloprid
has become the most successful neonicotinoid insecticide, representing 41.5% of
neonicotinoid use [174, 175]. Imidacloprid is used on various of vegetables, grains, and
turf to control insect pests as well as on pets to control ectoparasitic arthropods [175177]. Imidacloprid is also known to be persistent in soil with a photolysis half-life of 39
days and an aerobic half-life of ~3 years [185]. The above findings suggest a high
potential for human exposure to imidacloprid. In addition, the use of imidacloprid and
two other neonicotinoids were restricted by the European Commission in 2013 due to
their potential role in the collapse of bee populations [43].
Epidemiological studies have suggested a link between persistent organic
pollutants, including insecticides, and the risk of obesity and its associated pathology[60,
91, 188-190]. Our previous studies have demonstrated that several pesticides, including
imidacloprid, promotes adipogenesis in 3T3-L1 adipocytes and induces insulin resistance
in C2C12 myotubes [6, 9, 196-198]. Our recent publication also reported that oral
imidacloprid exposure promotes high fat diet-induced adiposity and insulin resistance in
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male C57 BL/6J mice [259]. It is not known, however, whether imidacloprid exposure
alone or together with high fat diet will exacerbate obesity and insulin resistance
symptoms in female mice. Thus, the current study was to determine if oral exposure to
imidacloprid would aggravate high fat diet-induced adiposity and insulin resistance in
female C57BL/6J mice. The role of AMPKα in imidacloprid-induced adipogenesis in
3T3-L1 adipocytes was also determined.

5.2 Materials and Methods
5.2.1 Materials
3T3-L1 preadipocytes and C2C12 myoblasts were obtained from American Type Culture
Collection (Manassas, VA). Fetal bovine serum (FBS), horse serum (HS), methylisobutylxanthin,
insulin, dexamethasone, phosphatase and protease inhibitor cocktail, and 5-aminoimidazole-4carboxamide ribonucleotide (AICAR) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Imidacloprid (>98%, CAS: 138261-41-3) was obtained from Chem Service Inc. (West
Chester, PA, USA). Five-week-old female C57BL/6J mice were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA). Semi-purified powdered diets (TD 94048, 4% fat w/w, low
fat diet and TD 07518, 20% fat w/w, high fat diet) were prepared based on Harlan Laboratories
(Madison, WI, USA) diets. Food ingredients were purchased from Bio-Serv (Flemington, NJ,
USA). Serum insulin level was determined with mouse insulin ELISA kit from ALPCO (Salem,
NH, USA). Non-esterified fatty acid assay kit was purchased from Wako Life Sciences, Inc.
(Mountain view, CA, USA). Glucose and total cholesterol assay kits were from Genzyme
Diagnostics (Charlottetown, PE, Canada). Mouse leptin assay kit was from R & D Systems
(Minneapolis, MN, USA). Mem-PER™ Plus Membrane Protein Extraction Kit, BCA protein kit,
Infinity™ triglycerides reagent, dichlorodihydrofluorescein diacetate (H2DCFDA), N-acetyl
cysteine (NAC), and protein A-sepharose 4B conjugate were obtained from Thermo Fisher
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Scientific (Waltham, MA, USA). Radioimmunoprecipitation assay (RIPA) buffer with 1%
protease inhibitor was from Boston Bioproducts Inc. (Ashland, MA, USA). Rabbit antibodies for
mouse acetyl-CoA carboxylase (ACC), phosphorylated ACC (pACC), AMP-activated protein
kinase α (AMPKα), phosphorylated AMPKα (pAMPKα), and horseradish peroxidase-conjugated
goat anti-rabbit IgG were obtained from Cell Signaling Technology (Beverly, MA, USA). Rabbit
antibodies for β-actin were purchased from Santa Cruz Biotechnology (Dallas, Texas, USA).
Rabbit antibody for Ca2+/calmodulin-dependent protein kinase β (CAMKKβ) was purchased from
Abcam Inc. (Cambridge, MA, USA). Human recombinant insulin (Novolin, 100 U/ml) was
obtained from Novo Nordisk Pharmaceuticals Industries Inc. (Seattle, WA, USA). Dextrose
(50%) and bacteriostatic 0.9% sodium chloride solution were from Hospira, Inc. (Lake Forest, IL,
USA). Dulbecco's Modified Eagle Medium (DMEM), dimethyl sulfoxide (DMSO), and other
chemicals were from Fisher Scientific (Pittsburgh, PA, USA).

5.2.2 Animals and diet
All animal work was performed using the guidelines approved by the Institutional
Animal Care and Use Committee at the University of Massachusetts under protocol number
2016-0011. Mice were housed in a humidity and temperature-controlled room with a 12-h
light/dark cycle. The compositions of diets were as previously described [259]. Water and diet
were given to mice ad libitum and each changed twice a week. Body weight and food intake were
monitored weekly. After adaptation, the mice were fed a control diet (4% fat w/w) and subjected
to baseline insulin tolerance and glucose tolerance tests. Mice were then divided into low fat and
high fat dietary groups with four imidacloprid treatment doses (0, 0.06, 0.6, and 6 mg/kg bw/day),
respectively. The treatment lasted for 12 weeks. Doses of imidacloprid were based on previous
publication [259]; the highest imidacloprid dose was no-observed-adverse-effect-level (NOAEL)
of imidacloprid at 5.7 mg/kg bw/day and the lowest dose of imidacloprid was estimated average
daily intake of imidacloprid of 60 µg/kg body weight/day [199-201]. Imidacloprid content in low
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fat diets were 0, 0.47, 4.7, and 47 mg imidacloprid/kg diet. The content of imidacloprid in high
fat diets were 0, 0.636, 6.36, and 63.6 mg imidacloprid/kg diet. At the end of the study, the
average imidacloprid consumption was 0, 0.07, 0.69, and 6.69 mg/kg bw/day in low fat dietary
groups and 0, 0.08, 0.74, and 6.66 mg/kg bw/day in high fat dietary groups. There were no
differences in imidacloprid intakes between low vs. high fat diet groups at the same doses.
At the end of the experiment, mice were fasted for 4 h before being sacrificed by CO 2
asphyxiation. Blood was collected by cardiac puncture and then centrifuged at 2000 g for 20
minutes to collect serum. Part of omental adipose tissue was first fixed in 10% phosphatebuffered formalin, and then used for paraffin sectioning [204]. The adipocyte size was measured
as previously described [259]. The other parts of the omental adipose tissue and all other organs
were snap frozen with liquid nitrogen and kept at -80 C. The levels of total non-esterified fatty
acids (NEFA), leptin, cholesterol, triglyceride (TG), and insulin in serum were determined with
commercial kits following the manufacturers’ instructions. The homeostasis model assessmentinsulin resistance (HOMA-IR) score, insulin tolerance test (ITT), glucose tolerance test (GTT)
were performed as previously described [259].

5.2.3 Serum parameters
The levels of total cholesterol, leptin, non-esterified fatty acids (NEFA), triglyceride (TG)
and insulin in serum will be determined with commercial kits following the manufacturers’
instructions.

5.2.4 Insulin tolerance test
Insulin tolerance test (ITT) will be performed during adaptation and treatment at week 5
and week 9 as previously described [202]. All mice will be fasted for 4 h. Blood glucose from the
tail vein will be measured at 0, 15, 30, 60 and 120 min post intraperitoneal injection of insulin
solution (0.75 U/kg body weight), with a blood glucose meter, Advocate Redi-Code+ (Advocate
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Meters Inc., Dorado, Puerto Rico). The areas under the curve (AUC) will be calculated with
Sigma Plot 11.0 (Systat Software, Inc., San Jose, CA, USA).

5.2.5 Glucose tolerance test
Glucose tolerance tests (GTT) will be performed during adaptation and treatment at week
6 and week 11 as described previously [202]. All mice will be fasted for 6 h before the first
measurement of blood glucose from the tail vein and blood glucose will be measured with a
blood glucose meter (0 min). Then, 20% glucose solution (2 g glucose/kg of body weight) will be
administered intraperitoneally and blood glucose levels will be further monitored at 15, 30, 60,
and 120 min. Blood insulin level will be measured at 0, 30, 60 and 120 min with mouse insulin
ELISA kit from ALPCO (Salem, NH, USA). AUC will be calculated with Sigma Plot. The
homeostasis model assessment- insulin resistance (HOMA-IR) score will be calculated with
HOMA-IR calculator (University of Oxford) [203].

5.2.5 Adipocyte size measurement
Epididymal adipose tissue will be fixed in 10% phosphate-buffered formalin and
processed for paraffin sectioning [204]. Tissue sections (4 µm) will be cut and stained with
hematoxylin and eosin (HE) staining. Pictures will be taken with Olympus CK2 inverted
microscope (Olympus, Tokyo, Japan) (100 x magnification) and microscope eyepiece camera
(AmScope, Irvine, CA). Adipocyte size will be measured as previously described with Image J
software with minor modification [205]. Mean area of 50 cells from each sample will be
measured with Image J software. Briefly, the pictures of calibration slide (AmScope, Irvine, CA)
will be taken under the same settings as the tissue sections and will be used to set the scale in
image J, then the area of the adipocytes will be measured with Image J.
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5.2.6 mRNA expression analysis
Total RNA were extracted as previously described.[259] Tumor necrosis factor α (TNFα) and 18S ribosomal RNA (18S rRNA) were analyzed. Real-time polymerase chain reaction
(PCR) was performed as previously described [259]. Mm00443258_m1 (TNFα) and
Mm03928990_g1 (18S rRNA) taqman probe-based gene expression assay kits were from Thermo
Fisher Scientific (Waltham, MA, USA).

5.2.7 Immunoprecipitation and immunoblotting
Proteins from mouse tissues were extracted, quantified and immunoblotted as previously
described [198, 259]. For the detection of the phosphorylation of serine 307 on insulin receptor
substrate (IRS1) (p-IRS1), cell lysates (500 µg of protein) were immunoprecipitated with IRS1
and protein G beads overnight at 4 °C before immunoblotting.

5.2.8 Cell culture
3T3-L1 preadipocytes were cultured and differentiated as previously described [198].
3T3-L1 cells were maintained in DMEM with 10% FBS at 37°C. Two days after confluence (day
0), cells were differentiated into adipocytes with a mixture of methylisobutylxanthin (0.5 mM),
dexamethasone (1 µM), and insulin (1 µg/mL) in DMEM containing 10% FBS. On day 2, the
medium was replaced with DMEM with 10% FBS and insulin (1 µg/mL). Starting from day 4,
medium was changed with DMEM containing 10% FBS every two days until day 8. 3T3-L1 cells
were treated with imidacloprid (10 µM) or AICAR (40 µM) for 8 days by adding stock solution
of imidacloprid or AICAR in dimethyl sulfoxide, both in DMSO, with all treatments having a
final concentration of 0.02% DMSO. The concentration of imidacloprid and AICAR were based
on our previous studies [9, 196, 198].
C2C12 cells were maintained in DMEM with 10% FBS at 37 °C. When the cells reach
80% confluence, they were differentiated into myotubes in DMEM with 2% horse serum for 6
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days. The myotubes were pre-treated with or without NAC (10 mM) for 30 min [260] and then 10
µM imidacloprid was added for additional two days.

5.2.9 Determination of cellular oxidative status
We measured cellular oxidative status based on a previous method [261], where the
nonfluorescent dye H2DCFDA is converted to the highly fluorescent 2',7'-dichlorofluorescein
(DCF) after being oxidized by various oxidants [261]. After imidacloprid treatments, cells were
incubated with 10 µM H2DCFDA for 30 minutes. Cells were washed three times with PBS,
immediately harvested and lysed with RIPA buffer. The fluorescence of the cell lysate
supernatant was determined at excitation/emission 485/520 nm with SpectraMax
spectrophotometer (Molecular Devices, Sunnyvale, CA). The fluorescence was then normalized
to the protein concentration of the cell lysate supernatant as measured by the BCA protein kit.

5.2.10 Statistical analyses
PROC MIXED procedure was utilized to analyze data with the SAS software (Version
9.3, SAS Institute Inc., Cary, NC, USA). For the result of body weight (Figure 6.1A), two-way
repeated measure Analysis of Variance (ANOVA) and the slice option in the Least Square (LS)
means statement were used to determine the differences at each time point. For all other results in
mice, two-way ANOVA along with LS means statement was used. The Tukey-Kramer’s method
was applied for the multiple comparisons among the groups. If there were significant interactions
between diet and imidacloprid, letters were used in the figures to present the differences between
each group. When there were no interactions between diet and imidacloprid, brackets were used
in the figures to represent differences between imidacloprid treatments and control groups. Cell
culture data (Fig. 6.5 & 6.6) were analyzed by one-way ANOVA followed by PROC mixed with
LS means statement. Tukey’s test was used for the multiple comparisons among the groups.
P<0.05 were considered as statistically significant.
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5.3 Results
5.3.1 Imidacloprid enhanced body weight gain and adipocyte size in high fat diet-fed mice
Overall, there were significant effects of dietary fat, imidacloprid, time, and their
interactions (imidacloprid x diet x time) on body weight (Fig. 5.1A). Both dietary fat and
imidacloprid had significantly increased body weight gain with a significant interaction between
dietary fat and imidacloprid (Fig. 5.1B, 133% increase in high fat compared to low fat diet and
10% increase in imidacloprid treatments compared to the controls). No differences in body
weight gain were observed among any of the groups in low fat diet-fed mice (Fig. 5.1A). In high
fat diet-fed mice, imidacloprid (0.6 mg/kg bw/day) resulted in a significant increase in body
weight compared to the control group starting from week 5 and maintained this trend throughout
the experiment (~15-22% increase compared to the controls, P<0.05 for all weeks from 5 to 12)
(Fig. 5.1A). Among high fat diet-fed groups, imidacloprid at 0.6 mg/kg bw/day treatment group
had greater weight gain, 71% increase compared to the high fat diet-fed control (P=0.0167) (Fig.
5.1B).
The calorie consumption of mice is shown in Fig. 5.1C.

Both dietary fat and

imidacloprid significantly affected the calorie intake without interaction. High fat diet-fed mice
consumed 12% more calorie than mice fed on low fat diet (Fig. 5.1C) and imidacloprid fed mice
have 6% decrease in calorie intake compared to mice in the control groups. However, mice fed
with 6 mg/kg bw/day imidacloprid had 12% less calorie intake compared to the control groups
(P=0.0223) (Fig. 5.1C).
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Figure 5.1. Effects of imidacloprid on body weight, body weight gain, adipocyte size and food
intake. Mice were fed with low or high fat diet supplemented with imidacloprid (0, 0.06, 0.6, and
6 mg/kg bw/day) for 12 weeks. (A) Body weight was monitored weekly; (B) Body weight gain
over 12 weeks; (C) Total calorie intake; (D) Representative pictures of epididymal adipose tissues
after H&E staining (100 x magnifications); (E) Adipocyte size. The mean area of 50 cells from
each sample were measured with image J. Numbers are mean ± S.E. (n=5-7 for A, B, D, and n=34 for E). Means with different letters were significantly different at P<0.05.
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5.3.2 Effects of imidacloprid on organs and tissue weights
Organs and tissues weights are shown in Table 5.1. There was a significant dietary fat
effect, but neither an imidacloprid effect nor their interactions were evident on liver, heart, spleen,
and kidney weights. Neither dietary fat nor imidacloprid treatments resulted in any effects on
pancreas. There were significant effects of dietary fat and imidacloprid treatments and with their
interactions on omental and total adipose tissue weights (92-98% increase in high fat compared to
low fat diet and 11-17% increase in imidacloprid treatments compared to the controls). In mice
fed with high fat diet, animals treated with imidacloprid (0.6 mg/kg bw/day) had greater omental
(45% increase, P=0.0416) and total adipose tissue weights (40% increase, P=0.0391) when
compared with the control group.
Histological analysis revealed significantly increased effects of both dietary fat and
imidacloprid treatments and with their interaction on omental adipocyte size (52% increase in
high fat compared to low fat diet and 17% increase in imidacloprid treatments compared to the
controls, Fig. 5.1D & 5.1E). Compared with the high fat diet-fed control group, imidacloprid (0.6
mg/kg bw/day) treatment markedly increased adipocyte size (45% increase, P=0.0063) in the
high fat diet-fed control mice (Fig. 5.1D & 5.1E)
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Table 5.1. Organ Weights (% of body weight)

Low fat diet

High fat diet

Imidacloprid (mg/kg BW/day)

P-value

Imidacloprid (mg/kg BW/day)

Control

0.06

0.6

6

Control

0.06

0.6

6

Dietary
fat

Imidacloprid

Interaction

Liver

4.04 ± 0.27

4.45 ± 0.35

4.56 ± 0.17

4.87 ± 0.25

3.45 ± 0.26

3.63 ± 0.16

3.79 ± 0.13

3.36 ± 0.15

<0.0001

n.s.

n.s.

Heart

0.52 ± 0.02

0.54 ± 0.03

0.50 ± 0.01

0.48 ± 0.01

0.47 ±0.03

0.46 ± 0.02

0.40± 0.02

0.42 ± 0.03

<0.0001

n.s.

n.s.

Spleen

0.37 ± 0.03

0.43 ± 0.07

0.35 ± 0.01

0.36 ± 0.02

0.37 ± 0.04

0.31 ± 0.01

0.26 ± 0.01

0.29 ± 0.01

0.017

n.s.

n.s.

Kidney

1.30 ± 0.06

1.31 ± 0.08

1.27 ± 0.02

1.19 ± 0.02

1.17 ± 0.05

1.15 ± 0.05

1.05 ± 0.03

1.09 ± 0.04

0.0002

n.s.

n.s.

Pancreas

1.04 ± 0.09

1.06 ± 0.08

0.96 ± 0.04

0.93 ± 0.03

1.06 ± 0.16

0.93 ± 0.10

0.82 ± 0.05

0.85 ± 0.04

n.s.

n.s.

n.s.

Omental

3.00 ± 0.28c

2.82 ± 0.23c

2.60 ± 0.27c

3.34 ± 0.51bc

4.62 ± 0.38b

4.71 ± 0.69ab

6.69 ± 0.39a

6.63 ± 1.19a

<0.0001

0.010

0.0375

Subcutaneous

2.45 ± 0.19abc

2.32 ± 0.17c

2.22 ± 0.24c

2.24 ± 0.39c

4.26 ± 0.41a

4.22 ± 0.68ab

5.89± 0.31a

5.69 ± 0.38a

<0.0001

n.s.

0.029

Retroperitoneal

1.01 ± 0.13

0.91 ± 0.17

0.90 ± 0.13

1.34 ± 0.18

2.16 ± 0.21

2.10 ± 0.39

2.93 ± 0.16

2.82 ± 0.12

<0.0001

n.s.

n.s.

Mesenteric

0.88 ± 0.15

0.80 ± 0.09

0.81 ± 0.12

1.07 ± 0.16

1.47 ± 0.16

1.50 ± 0.35

2.03 ± 0.19

1.80 ± 0.15

<0.0001

n.s.

n.s.

Total

7.34 ± 0.85cd

6.85 ± 0.35d

6.53 ± 0.81d

7.99 ±
0.97bcd

12.5 ± 1.25b

10.0 ± 3.09bc

17.5 ± 1.06a

16.9 ± 1.08a

<0.0001

0.026

0.028

Adipose tissue

Mice were treated with three doses of imidacloprid (0.06, 0.6 and 6 mg/kg bw/day). Values represent means ± SE (n=5-7).
Means with different superscripts within the same row are significantly different at P<0.05. Abbreviations: n.s., not significant.
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Table 5.2. Serum Parameters

Low fat diet

High fat diet
P-value

Imidacloprid (mg/kg BW/day)

Imidacloprid (mg/kg BW/day)

Control

0.06

0.6

6

Control

0.06

0.6

6

Dietary
fat

Imidacloprid

Interaction

Glucose
(mg/dL)

154.3 ± 27.1

139.9 ± 23.7

145.1 ± 10.1

144.3 ± 5.9

152.5 ± 15.1

150.9 ± 13.2

170.6 ± 9.3

141.9 ± 9.4

n.s.

n.s.

n.s.

Insulin
(ng/mL)

0.70 ± 0.09

0.79 ± 0.13

0.62 ± 0.08

1.14 ± 0.18

1.02 ± 0.10

1.00 ± 0.21

1.19 ± 0.25

1.45 ± 0.14

0.0025

0.0269

n.s.

Leptin
(ng/mL)

16.1 ± 5.0

19.8 ± 4.2

12.3 ± 3.8

29.1 ± 6.8

36.8 ± 5.0

47.7 ± 21.7

52.5 ± 4.0

69.7 ± 11.0

<0.0001

0.0387

n.s.

TG
(mg/dL)

63.1 ± 1.9

83.7 ± 7.2

75.3 ± 7.2

73.0 ± 3.8

59.9 ± 5.1

67.9 ± 3.7

66.3 ± 1.5

73.1 ± 2.1

0.0378

0.0343

n.s.

Cholesterol
(mg/dL)

65.3 ± 4.9

73.0 ± 6.5

71.3 ± 3.6

62.4 ± 5.2

73.1 ± 2.4

68.6 ± 2.8

89.3 ± 8.3

84.8 ± 8.5

0.0098

n.s.

n.s.

NEFA
(mEq/L)

1.3 ± 0.3

1.5 ± 0.3

1.3 ± 0.3

1.0 ± 0.1

1.2 ± 0.2

1.3 ± 0.1

1.4 ± 0.2

1.8 ± 0.4

n.s.

n.s.

n.s.

Mice were treated with three doses of imidacloprid (0.06, 0.6 and 6 mg/kg bw/day). Values represent means ± SE (n=5-7). Means with different superscripts within the same row are significantly
different at P<0.05. Abbreviations: n.s., not significant; TG, triglyceride; NEFA, non-esterified fatty acid.
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5.3.3 Effects of imidacloprid on serum markers
Analyses of serum markers are shown in Table 5.2. There were significant effects of both
dietary fat and imidacloprid treatments (without interaction) on serum insulin, leptin, and TG
levels. There were 43% increase for insulin, 167% increase for leptin, and 9% decrease in high fat
over low fat diet fed mice. There were 20% increase for insulin, 46% increase for leptin, and 19%
increase in imidacloprid treatments over the controls. Mice treated with 6 mg imidacloprid/kg
bw/day had higher blood insulin and leptin levels compared with the respective control groups
(50% and 87% increase with P=0.0363 and 0.0271, respectively). Mice fed with imidacloprid
(0.06 mg/kg bw/day) had higher levels of TG (23% increase, P=0.0458) than the control groups.
Dietary fat, but not imidacloprid, had significant effects on cholesterol levels (16% increase in
high fat compared to low fat diet groups). Neither dietary fat nor imidacloprid had any effect on
serum glucose or NEFA levels in the current study.

5.3.4 Influence of imidacloprid on glucose homeostasis
The effects of treatment with imidacloprid or dietary fat on glucose homeostasis were
determined by ITT, GTT, and HOMA-IR (Fig. 5.2). There were no significant differences of the
ITT values between any of the groups over time as shown in Fig. 5.2A-5.2C. There was a
significant effect of dietary fat on GTT values in weeks 6 & 11 (7% and 19% increase in high fat
groups compared to low fat groups, respectively), without imidacloprid or interaction effects (Fig.
5.2E & 5.2F).

5.3.4 Effects of imidacloprid on AMPKα pathway and TNFα in white adipose tissue
AMPK is a master regulator of energy metabolism and AMPK activation results in the
inhibition of lipogenesis [212]. Based on previous publications [196, 259], we have determined
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the effects of imidacloprid and high fat diet on AMPK, one of its downstream markers (acetyl
Co-A carboxylase, ACC) and one of its upstream regulators (Ca2+/calmodulin-dependent protein
kinase β, CaMKKβ) [213, 214] from omental adipose tissue (Fig. 5.3A-5.3D). There were both
dietary fat and imidacloprid effects on the expression of CaMKKβ without interaction (20%
decrease in high fat compared to low fat diet and 18% decrease in imidacloprid treatments
compared to the controls, Fig. 5.3A). Imidacloprid (0.6 and 6 mg/kg bw/day) had reduced
expression of CaMKKβ compared to controls (21% and 24% reduction with P= 0.0099 and
0.0023, respectively) (Fig. 5.3A). There were significant effects of imidacloprid and imidacloprid
& dietary fat interaction on the ratio of pAMPKα/AMPKα (7% decrease in high fat compared to
low fat diet and 22% decrease in imidacloprid treatments compared to the controls, Fig. 5.3B).
High fat diet and imidacloprid (0.6 and 6 mg/kg bw/day) fed mice had significantly decreased
ratio of pAMPKα/AMPKα compared to high fat diet-fed control (45% and 58% reduction with
P= 0.0064 and 0.0002, respectively) (Fig. 5.3B). There were dietary fat and imidacloprid as well
as their interaction effects on the ratio of phosphorylated ACC/ACC (pACC/ACC) (14% decrease
in high fat compared to low fat diet and 16% decrease in imidacloprid treatments compared to the
controls, Fig. 5.3C). High fat diet fed mice treated with imidacloprid at 0.06 and 6 mg/kg bw/day
had significantly lower pACC/ACC ratios compared to high fat diet-fed control (48% and 43%
reduction with P=0.0061 and 0.0172, respectively) (Fig. 5.3C). The current results indicate that
oral administration of imidacloprid enhance lipogenesis in part via AMPKα dependent pathway
in mice white adipose tissue.
There were dietary fat and imidacloprid as well as their interaction effects on TNF-α
mRNA level (127% increase in high fat compared to low fat diet and 70% increase in
imidacloprid treatments compared to the controls, Fig. 5.3E). High fat diet-fed mice treated with
imidacloprid at 0.6 and 6 mg/kg bw/day had significantly higher levels of TNFα compared to
high fat diet-fed controls (165% and 182% increase, respectively, with P<0.0001 for both) (Fig.
5.3E).
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Figure 5.2. Effects of imidacloprid on insulin tolerance test (ITT) (A, B, C), glucose tolerance test
(GTT) (D, E, F) as determined as the area under the curve (AUC) and HOMA-IR (G). Mice were
fed with low or high fat diet supplemented with imidacloprid (0, 0.06, 0.6, and 6 mg/kg bw/day)
for 12 weeks. ITT was measured during adaptation period, weeks 5 and 9. GTT was measured
during adaptation period, weeks 6 and 11. Blood was collected from the tail vein, and glucose
levels were determined at 0 min. Insulin (ITT) or glucose solutions (GTT) were subsequently
administered by intraperitoneal injection and glucose level were further measured at 15, 30, 60
and 120 min post injection. HOMA-IR score was calculated at week 12 with HOMA-IR
calculator43. Numbers represent means ± SE (n=5-8).
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Figure 5.3. Effects of imidacloprid on AMPKα pathway and TNFα expression in the white
adipose tissue. Mice were fed with low or high fat diet supplemented with imidacloprid (0, 0.06,
0.6, and 6 mg/kg bw/day) for 12 weeks. A. CaMKKβ, Ca2+/calmodulin-dependent protein kinase
β; B. pAMPKα/AMPKα, phosphorylated AMP-activated protein kinase-α/AMP-activated protein
kinase-α; C. pACC/ACC, phosphorylated acetyl-CoA carboxylase/acetyl-CoA carboxylase; D.
Representative pictures; E. TNFα, tumor necrosis factor α. Numbers represent mean ± S.E. (n=46). Means with different letters were significantly different at P<0.05.
5.3.4 Effects of AMPKα activation on imidacloprid induced adipogenesis
To further determine the role of AMPKα activation on imidacloprid-induced
adipogenesis, 3T3-L1 adipocytes were co-treated with imidacloprid and AICAR, an AMPK
activator [198]. Consistent with results in Fig. 5.3 and the previous report [196], imidacloprid
treatment alone increased fat accumulation compared to control group (P=0.0012) (Fig. 5.4A).
AICAR treatment alone decreased fat accumulation (P<0.0001) as expected [198]. However, cotreatment of AICAR and imidacloprid resulted in significantly decreased fat accumulation to a
level similar to AICAR alone (P=0.0012, compared to control). Consistently as AMPK activation

82

was reported to decrease the expression of Fig. 5.4B-5.4D further shows that AICAR and
imidacloprid co-treatment significantly decreased the expression of C/EBPα (P<0.0001), while
increase the ratio of pAMPKα/AMPKα to the level similar to AICAR alone. These findings are
consistent with previously reported findings where AMPK activation was reported to decrease the
expression of C/EBPα [163]. These results suggest that imidacloprid promotes adipogenesis via
the AMPKα-mediated pathway in 3T3-L1 adipocytes.

Figure 5.4. Influence of AMPKα activation on adipogenesis induced by imidacloprid in 3T3-L1
adipocytes. A. Triglyceride; B. Representative pictures; C. C/EBPα, CAATT element binding
protein-α; D. pAMPKα/AMPKα, phosphorylated AMP-activated protein kinase-α/AMP-activated
protein kinase-α. Cells were treated with imidacloprid (10 µM) or AICAR (40 µM) for 8 days.
Numbers represent mean ± S.E. (n=3). Means with different letters were significantly different at
P<0.05.
5.3.5 Effects of imidacloprid on insulin signaling pathway in C2C12 myotubes
Phosphorylation of IRS1 Serine 307 (pIRS1 S307) is associated with the inhibition of
insulin signaling [262]. Figure 6.5A & 6.5B showed that imidacloprid significantly decreased
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insulin-stimulated phosphorylation of protein kinase B (AKT), while increasing the
phosphorylation of IRS1 S307. Imidacloprid (10 µM) was further observed to elevate the
oxidative stress (Fig. 5.5C), and NAC, an oxygen free radical chelator [263], partially reversed
the decreased phosphorylation of AKT induced by imidacloprid (Fig. 5.5D). These results
suggest that the elevated cellular oxidative stress is partially responsible for insulin resistance
induced by imidacloprid.

Figure 5.5. Effects of imidacloprid on insulin signaling and oxidative stress in C2C12 myotubes.
A. pAKT/AKT, phosphorylated AKT/AKT; B. pIRS1/IRS1, phosphorylated insulin receptor
substrate 1 (Serine 307)/insulin receptor substrate 1; C. Effects of imidacloprid on the oxidative
stress; D. N-acetyl cysteine (NAC, 10 mM) partially restored imidacloprid induced decrease of
pAKT. Immunoprecipitation was first performed with IRS1 antibody and then immunoblotted
with pIRS1 or IRS1 antibodies. Cells were differentiated into myotubes for 6 days in DMEM
with 2% horse serum and then myotubes were treated with imidacloprid (10µM) for 2 days. One
day before insulin stimulation, media were changed to F-12K with 2% horse serum. Protein
expression was determined after treatment with or without insulin (100 nM) for 15 minutes.
Numbers represent mean ± S.E. (n=3). Means with different letters were significantly different at
P<0.05.
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5.4 Discussion
In the current in vivo study, oral exposure to imidacloprid at or lower than the NOAEL,
aggravated high fat diet-induced weight gain and elevated serum insulin levels in C57BL/6J
female mice. The current in vitro results indicate that imidacloprid may elicit these effects by
post-translational regulation of AMPK pathway in white adipose tissue. Although we did not
observe any significant effect of imidacloprid on insulin resistance in the current female study,
imidacloprid might induce insulin resistance via TNFα and/or oxidative stress-mediated
mechanism as seen in previous male study [259].
Previously oral administration of imidacloprid to mice or rats at 15 or 20 mg/kg bw/day
significantly decreased body weight, whereas mice exposed to 5 or 10 mg/kg bw/day showed no
change in body weight when fed chow diet (low fat diet) [193, 264]. Our previous publication
first reported the interaction between oral imidacloprid administration (at lower than 6 mg/kd
bw/day) and high fat diet in male mice, resulting in significantly induced weight gain in male
mice [259]. We now show that imidacloprid and high fat diet significantly induced weight gain
also in female mice. There is only one other study reporting the role of high fat diet potentiating
the effect of environmental contaminants on weight gain where persistent organic pollutants
(POP) in crude fish oil were reported to potentiate high fat diet (20% wt/wt corn oil)-induced
visceral adipose tissue and weight gain compared with refined salmon oil (without POP) after 4
weeks in male Sprague-Dawley rats [191]. This study failed, however, to compare the role of
POP in low fat diet. Therefore, it was not clear if high fat diet contributed to the effects of POP in
this model. Thus, the significance of the current study and our previous male study is the
interaction between low dose imidacloprid (at or lower than an NOAEL of 5.7 mg
imidacloprid/kg bw/day) and high fat diet on the development of obesity. The current results
further support that effects of imidacloprid and high fat diet on weight gain was independent of
the sex of mice. Although the mechanism of how high fat diet induces increased weight gain
following imidacloprid treatment is still unknown, we speculate that high-fat diet and
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imidacloprid interaction is independent of type of fat used, because both the current study
(soybean oil used) and study from Ruzzin et al. (2010) (corn oil used) observed similar weight
gain by treatment and high fat diets. It is possible that high fat diet induces metabolic stress and
imidacloprid further exacerbate this process, resulting in excess weight gain in high fat diet-fed
mice. Alternatively, we cannot exclude the possibility that low and high fat diets might have
different effects on the bioavailability of insecticides, thus leading to the differences observed in
this study.
In addition to high-fat diet induced weight gain, Ruzzin et al [191] also reported that
persistent organic pollutants (POP) in crude fish oil promoted high fat diet (20% wt/wt corn oil)induced insulin resistance compared to refined salmon oil (without POP) in male rats. Others
have reported that oral administration of 20 mg imidacloprid/kg bw/day for 90 days with chow
diet (low fat diet) increased blood glucose level, whereas 10 mg imidacloprid/kg bw/day did not
affect blood glucose in female rats [193]. Our previous study reported that imidacloprid treatment
(0.6 and 6 mg/kg bw/day for 12 weeks) exacerbated high fat diet (soybean oil)-induced insulin
resistance in male mice [259]. In the current study, however, the 12-week imidacloprid exposure
significantly increased serum insulin levels without influence on insulin tolerance and glucose
tolerance in high fat diet-fed female mice. These findings suggest a potential sex differences in
susceptibility to high fat diet-induced insulin resistance. It is possible that compared with male
mice, female mice may require longer time, and/or higher treatment doses to develop metabolic
disorders under the experimental conditions used. In support of this contention, others have
reported that female mice were resistant to high fat diet-induced glucose intolerance and insulin
resistance [265], which may be due to estrogens that are protective against the development of
metabolic syndrome and insulin resistance in female rodents [266].
In the previous male study [259], there were interactions between imidacloprid and
dietary fat on CaMKKβ expression and AMPK phosphorylation in adipocytes. In the current
study, however, there is only an interaction between imidacloprid and dietary fat on AMPK
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phosphorylation, but not on CaMKKβ expression. Thus, whether imidacloprid affects AMPKα
activation via CaMKKβ or other upstream regulators in high fat diet-fed female mice needs to be
further determined. In addition, imidacloprid is an agonist on nicotinic acetylcholine receptors at
low concentrations, but blocks them at high concentrations [39]. It is not clear from the results of
the current study whether imidacloprid induces adipogenesis and/or insulin resistance by way of
or independent of its action on nicotinic acetylcholine receptors in muscle or adipose tissue.
Imidacloprid (10 µM) exposure was previously reported to induce insulin resistance by
reducing both insulin-stimulated glucose uptake and phosphorylation of AKT in myotubes [9].
Imidacloprid was also reported to increase TNF-α, Interleukine-1β, and Interleukine-6 in mice
liver and brain [233]. TNFα is a proinflammatory cytokine released mainly from macrophages in
response to other physiological processes [267] and is known to inhibit insulin signaling by
activating protein tyrosine phosphatase by removing tyrosine phosphate groups from IRS-1 [267].
In addition, binding of TNFα to its receptors triggers a broad pattern of signaling cascades,
including c-Jun amino-terminal kinase (JNK), which cause insulin resistance by promoting serine
phosphorylation of IRS1 at 307, a negative regulator of insulin signaling [267]. In the current
study, imidacloprid increased TNFα expression in adipose tissue, which might contribute to
developing insulin resistance by imidacloprid.
Chronic oxidative stress is thought to be one of contributing factors to the development of
chronic diseases, including insulin resistance [268]. Oxidative stress was reported to stimulate the
serine kinase of p38 mitogen-activated protein kinase (p38 MAPK), which is correlated with
reduced insulin signaling and glucose transport [269]. Imidacloprid was previously reported to
cause oxidative stress [233, 234], and our current results from C2C12 muscle cells suggest that
imidacloprid reduces insulin-stimulated phosphorylation of AKT, partially mediated by oxidative
stress, further supporting the potential role of oxidative stress on imidacloprid’s effects on insulin
responsiveness. However, the in vivo effect of imidacloprid on insulin responsiveness, especially
in females, needs to be further determined.
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Imidacloprid is readily absorbed from the gastrointestinal tract and distributed in almost
all tissues [199]. Once absorbed, imidacloprid is degraded into several metabolites [199] and
excreted in the urine as glutathione and glycine conjugates of mercaptonicotinic acid and hippuric
acid [199]. Imidacloprid is regarded as moderately toxic, with oral LD50 of 420 mg/kg bw in rats,
and the typical symptoms of poisoning include cramps, fatigue, and muscle weakness, which
were not observed in the current study due to low doses used [252].
In conclusion, the current study reports that imidacloprid exposure (0.6 and 6 mg/kg
bw/day) promotes high fat diet-induced obesity in female C57BL/6J mice. Although the detailed
mechanisms on how imidacloprid interacted with high fat diet still needs to be clarified, the
results are significant in demonstrating a potential link between low level imidacloprid exposure
and high fat diet in augmenting obesity as well as insulin resistance.
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CHAPTER 6
FUTURE DIRECTIONS
The current results showed that both fipronil and imidacloprid promoted adipogenesis via
AMPKα-mediated mechanism in 3T3-L1 adipocytes. Whether fipronil and imidacloprid directly
targets AMPKα or through regulating other upstream markers or receptors need to be further
confirmed. Both fipronil and imidacloprid have been reported to increase intracellular calcium
concentrations in neuron cells [165, 270]. Based on reports that chronic elevation of intracellular
calcium might impair the activation of AMPK via calcium/calmodulin kinase kinase-β
(CaMKKβ) [166, 167] as well as induce insulin resistance [271], it is possible that fipronil and
imidacloprid may influence intracellular calcium levels, leading to altered adipogenesis via
CaMKKβ- and AMPK-mediated mechanisms as well as insulin resistance. This contention is
supported by the fact that imidacloprid decreased the expression of CaMKKβ in adipose tissue,
although fipronil’s effect on CaMKKβ remained to be determined. Fipronil and imidacloprid’s
effect on intracellular calcium in adipocytes and myotubes need to be further elucidated to
determine the underlying mechanisms of fipronil and imidacloprid on development of obesity and
insulin resistance.
Imidacloprid increased body weight gain and adiposity only in high fat diet-fed mice, but
not in low fat diet-fed mice. Currently, limited knowledge is known about how dietary fat
contributed to imidacloprid’s effect on obesity. It is possible that low and high fat diets might
have different effects on the bioavailability of insecticides, thus leading to the differences
observed in this study. It is also possible that high fat diet has given the mice metabolic stress and
imidacloprid further exacerbate this process. Further investigation on the absorption and
accumulation efficacy of imidacloprid when delivered orally in low-fat and high-fat diet are
needed.
Imidacloprid treatment resulted in sex-dependent responses on glucose metabolism.
Although it is not clear how sex differences affected imidacloprid’s effect on insulin resistance, it
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is possible that female mice may be more resistant to altered insulin responsiveness caused by
imidacloprid than males as estrogens were known to protect against the development of insulin
resistance [266].

Further investigation on the role of estrogen in development of insulin

resistance induced by imidacloprid especially in female mice (for example with estrogen receptor
knockout mice) would also be necessary to clarify the sex differences in imidaclorpid’s effects on
glucose metabolism.
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